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ABSTRACT
A number of studies have demonstrated that small metabolites can
react nonenzymatically with proteins to form covalent, addition products. An example of this type of reaction 1s the modification of
hemoglobin A by glucose to form the minor species hemoglobin A-|c« I"
this case, glucose reacts by forming a reversible Schiff base adduct with
the N-terminal valine of the B-chain of hemoglobin. The Schiff base
intermediate then slowly undergoes an Amadori rearrangement to produce a
stable ketoamine addition product.
The following studies investigate two novel aspects of nonenzymatic
addition reactions. The first is the demonstration that ketolic
steroids, i.e. steroids bearing a carbonyl function adjacent to a
hydroxyl group, can react with protein amino groups to form stable Heyns
rearrangement products. The second 1s the observation that reducing
sugars can react with the nucleotides of DNA to form covalent adducts.
The steroids which react with proteins include the glucocorticoids; such
as Cortisol and prednisolone, which contain side-chain ketols, and the
estrogen metabolite 16a-hydroxyestrone (16a0HE), which contains a ring
ketol.

The long-term therapeutic administration of glucocorticoids is

associated with many toxic manifestations and it was reasoned that one of
these effects, cataract formation, might be the result of the progressive
accumulation of protein bound glucocorticoid adducts. 16a-hydroxyestrone
on the other hand, has been reported to be present in elevated amounts in
the autoimmune disease Systemic Lupus Erythematosus (SLE). Protein
modification by this steroid might induce immune dysfunction by either
hapten formation or by covalently modifying immunoregulatory proteins.
Both Cortisol and 16a0HE react with albumin in vitro, modifing 2-3
discrete lysine residues. Structural analysis of model steroid-lysine
adducts showed that these products form through a Schiff base addition
reaction between the steroid carbonyl and the E-amino group of lysine.
The role of glucocorticold-protein adducts in cataract formation was
investigated first in two experimental models of the steroid-induced
cataract. The addition of the glucocorticoid, prednisolone, to the rat
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lens in culture resulted in a time and concentration dependent lens
opacification that correlated with the incorporation of [^HJprednisolone
into lens protein. The most extensively modified proteins were two
subunits of the lens crystallins, the major structural component of the
lens. In the rabbit, lens opacities similar in morpohology to human
steroid-induced cataracts were induced by the intravitreal injection of
glucocorticoids. These lesions also were associated with steroid
incorporation into lens protein.
In order to detect glucocorticoid adducts formed in vivo, a
radioimmunoassay was developed for these products utilizing antisera
produced against prednisolone which had been nonenzymatically attached to
albumin. Lens proteins from 33 normal and cataractous human lenses were
fractionated and assayed for prednisolone adducts by competitive radioimmunoassay.
Steroid adducts were detected only in lens proteins
obtained from the steroid cataracts, and at levels similar to those
observed in the rat and rabbit experimental models.
In vitro, prednisolone attaches to the amino groups of the lens
crystallins. This modification imparts on the crystallins an increased
susceptibility to sulfhydryl oxidation, leading with time to disulfide
bond exchange and the formation of high-molecular weight aggregates which
refract light. This effect was blocked by the pretreatment of lens
crystallins with the mild acetylating agent, acetylsalicylic acid.
Acetylation itself did not induce aggregation, but did prevent
prednisolone incorporation and the subsequent formation of high-molecular
weight aggregates.
The estrogen metabolite, I60OHE, reacts in vitro with a number of
proteins,

including

albumin,

hemoglobin,

and

erythrocyte

membrane

proteins. When added to whole blood however, 16a0HE reacts preferentially
with membrane proteins; for example, erythrocyte membrane proteins are
labeled to a greater than 15 fold higher specific activity than albumin. A
radioimmunoassay for the 16a0HE-lysine product was developed and a number
of proteins from both normal and SLE individuals were assayed for the
presence of these adducts . Women with SLE were found to have higher than
normal levels of 16a0HE modified proteins in erythrocyte and lymphocyte
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membranes. In the case of the erythrocyte there was a correlation
between the protein 16a0HE-lysine level and the circulating level of free
ISaOHE.

Glomerular basement membrane collagen also was analyzed and

found to contain high amounts of 16a0HE-lysine. It appears that the
level of 16a0HE modification of a given protein is proportional to its
biological lifespan and that, in relative terms, this level of modification is increased in SLE patients.
that

This is consistent with the idea

16a0HE adducts accumulate over a long time period, and that the

degree of protein modification 1s a time Integral of the free 16a0HE
level.
The increased level of 16a0HE-protein adducts in patients with an
autoimmune disease led to the possibility that these products might be
antigenic in some individuals. An enzyme-linked immunoassay for antiestrogen autoantibodies was developed and used to screen human plasma.
Unexpectedly, a number of normal, disease-free women were found to
display this anti-estrogen activity. On further analysis, it was found
that approximately 30% of normal women who had ever used oral contraceptive medication had sera which gave positive results on this assay.
Oral contraceptives contain the synthetic estrogen 17a-ethinylestradiol,
and this derivative has been observed previously to undergo enzymatic
conversion to products which react with proteins to form covalently bound
ligands.

Presumably, in some women, these protein-bound estrogens are

antigenic and induce antibody formation.

On the other hand, a few male

and female patients with SLE displayed this anti-estrogen antibody
activity without ever having been on oral contraceptives. This antiestrogen activity may represent an antibody formed to the endogenous
16a0HE-lysine adduct or alternatively, an autoantibody elicited in
response to another cross-reactive antigen. The role of these antiestrogen antibodies in the pathological sequelae of long-term contraceptive use or SLE is worthy of further investigation.
The second aspect of nonenzymatic reactions which were investigated
was the nonenzymatic modification of DNA by reducing sugars. In the case
of proteins, glucose derived Amadori products undergo further rearrangements, oxidations, and dehydrations to form fluorescent, cross-linking
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chromophores. This process, called nonenzymatic browning or the Maillard
reaction occurs in vivo. Long-lived structural proteins, such as
collagen and the lens crystallins, accumulate enough of these products
that they acquire many of the chemical properties characteristic of aged
proteins. Nucleic acids also are long-lived molecules in the resting
cell, and the accumulation of glucose-derived DNA adducts with time would
be expected to adversely affect DNA function.
The incubation of DNA or nucleotides with glucose-6-phosphate (G6P)
produced spectral changes similar to those described for the nonenzymatic
browning of proteins. The occurence of chemical modification was
verified by measuring the transfection efficiency of viral DNA after
incubation with glucose or G6P.

A loss of transfection potential

occurred that was first order with respect to time and sugar concentration. Glucose-6-phosphate also produced DNA strand scission in a time
and concentration manner, but at a rate which was significantly slower
than the rate of transfection inhibition.

It appears that reducing

sugars form adducts with the primary amino groups of nucleotides which
inhibit template function.

With time, these adducts undergo chemical

rearrangement which labilizes the glycosidic bond between the base and
the deoxyribose, causing depurination and DNA strand-scission.
Plasmid DNA modified by incubation with G6P was mutagenized when
assayed in a prokaryotic host. Structural analysis of these mutants
showed that many of the plasmids had undergone gross DNA alterations,
including insertions and deletions of several hundred base-pairs. The
ability of an endogenous sugar to induce such extensive DNA rearrangements suggests that nonenzymatic reactions of this type may represent an
important source of cellular mutations. The acumulation of glucosederived DNA adducts with time might be a mechanism for the decreased
genetic viability and increased tumorigenesis observed in the aged
organism.
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DTT: dithiothreitol.
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SDS: sodium dodecyl sulphate.
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INTRODUCTION.

2.

Within the last ten years, it has become apparent that a number of
endogenous, low-molecular weight substrates can react nonenzymatically
with macromolecules to form covalent addition products.

These reactions

are slow and since the rate is first order with respect to the reactive
substrate, the level of modification depends only on the substrate
concentration and the biological half-life of the affected macromolecule.
Table 1 lists molecules which have been shown to react nonenzymatically.
They include metabolites, such as cyanate, glucose, and acetaldehyde and
enzyme cofactors such as acetyl-CoA and S-adenosyl-methionine.

The first

class of compounds contain carbonyl groups which form addition products
with the primary amino groups of proteins.

The second class of reactive

substrates are enzymatic cofactors which serve to transfer an activated
acetyl or methyl group.

At a yery low frequency however, these groups

can add directly to an amino acid or nucleotide residue without the aid
of an enzyme.
The first metabolite shown to react nonenzymatically with proteins
was cyanate.

In 1960, Stark, Stein, and Moore (1) observed that cyanate,

which exists in equilibrium with urea, readily combined with and
inactivated ribonuclease.

Interest in carbamylation reactions increased

in the early 1970's when Cerami and Manning (2) provided the rationale
for the purported anti-sickling activity of urea.

At that time, the

administration of high concentrations of urea was reported to alleviate
the crisis phase of sickle-cell anemia.

Cerami and Manning found that

sodium cyanate could specifically carbamylate the N-terminal valine of
hemoglobin S and prevent red cell sickling.

Carbamylated proteins have

been detected in states associated with high blood urea, such as renal
failure and chronic diarrhea (3-4).

Attempts have been made recently to
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Nonenzymatic Addition Reoctions
Endogenous Substrates Target Molecules Reactive Residues
Cyanate

0N=C=O

r,
Glucose,
reducing sugars
Acetaldehyde

HC=0
I
HC-OH
R
0
II

Protein

Q-omino ocids,
lysine

Protein
DNA

Q-omino ocids,
lysine
A.G.C

Protein

Q-omino ocids
lysine, tyrosine

CH3CH
Acetylcoenzyme A

0
C0A-S-C-CH3

Protein

lysine

CH3
I ^

S-odenosylmethionine

e 1.

odenosine-S©
/
^-COOH
H2N

Protein
DNA

Summary of nonenzymatic addition

glutomote, osportote
A,G

reactions.
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link protein carbamylation with some of the pathological consequences of
high urea levels.

For example, since the oral administration of cyanate

was found to lead to cataract formation (5); Harding has postulated that
the high incidence of cataracts in the developing world might be
attributed to chronic diarrhea and the progressive carbamylation of lens
proteins (6).
The nonenzymatic

reaction which

has been studied the most

extensively is the reaction between glucose, a reducing sugar, and
protein amino groups.

Interest in nonenzymatic glycosylation jm vivo

began with the observation by Rahbar (7) in 1968 that diabetic patients
had elevated amounts of an electrophoretically "fast-moving" hemoglobin.
Subsequent work in several laboratories led to the identification of
hemoglobin A T Q as a modified hemoglobin formed post-translationally by
the attachment of glucose to the N-terminal valine of the beta-chain
(8-10).

The mechanism for this reaction is outlined in Figure 1.

reversible

A

Schiff base adduct is formed between the C-1 aldehyde and the

e-amino group of valine.

The condensation product, an aldosylamine, then

undergoes an Amadori rearrangement to form a 1-deoxyfructosyl

adduct.

The demonstration by Koenig and colleagues (11) that the amount of
hemoglobin A-jc reflected the integrated blood glcose over a three to four
week period spurred the use of this measurement as a clinical tool in
diabetes mellitus (12). Furthennore, the observation that many of the
sequelae of this disease occur in tissues that do not require insulin for
glucose transport led to the hypothesis that Increased protein glycosylation might account for many of the complications in diabetes.

A

number of proteins have been shown subsequently to be more glycosylated
in the diabetic individual. These include albumin (13), myelin (14),
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H3C

CH-

HjC
\

CH:
\

/

CH

CH

HgC-NH-CH-C-NH^^

HC=N-CH-C-NH'wv
HCOH
I
HOCH
I
HCOH
I
HCOH
I
CH2OH

/

0
Amadori
>

C=0
I
HOCH
I
HCOH
I
HCOH
I
CHgOH

0

Figure 1. The Amadori rearrangement between glucose and the
N-terminal valine of the 3-chain of hemoglobin.
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tubulin (15), lens crystallins (16), collagen (17), and erythrocyte
membrane proteins (18).
Perhaps the most biologically significant aspects of nonenzymatic
glycosylation

however, may be attributed to an observation made over 70

years ago by the French chemist Louis Maillard (19). He described a
chemical process, known today as nonenzymatic browning or the Maillard
reaction, which is initiated by the addition of reducing sugars to amino
groups.

With time, Amadori and other Schiff base rearrangement products

undergo a series of dehydrations, oxidations, and cyclizations to form
yellow-brown, fluorescent compounds which contain unsaturated rings and
nitrogen heterocycles.

When the amino groups of proteins are involved,

protein-bound, cross-linking

pigments form.

Products with the same

spectral and fluorescent properties as those of late-stage Maillard
products are associated in vivo with long-lived structural proteins, such
as collagen and the 1 ens-crystal 1 ins (20, 21).
aging,

long-lived

proteins

become

crosslinked, and less soluble (23).

more

In the course of normal

fluorescent

(22), more

In the diabetic individual these

protein changes are accelerated, as are a number of age-dependant,
physiological effects.

These include atherosclerosis (24), stiffening of

the lungs (25), and the large arteries (26), thickening of the capillary
and glomerular basement membranes (27, 28), and periarticular rigidity
(29).

Acceleration of these age-related complications in the diabetic

patients implicates the role of glucose and Maillard products in this
form of protein aging.
The third metabolite listed in Table 1 is acetaldehyde.

The

observation that non-diabetic, chronic alcohol abusers had elevated
levels of minor hemoglobins led to the demonstration that acetaldehyde
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(the oxidation product of ethanol) can form stable addition products with
proteins (30).

Chemically, these studies proved interesting because

tyrosine, a residue which cannot participate In Schiff base formation,
was found to be readily modified.

Acetaldehyde may be reacting with

tyrosine by forming an intermediate, electrophilic immonium cation.
These studies led to the hypothesis that protein modification by
acetaldehyde may contribute to some of the pathological sequelae of
chronic alcoholism,

such as peripheral neuropathy and an increased

susceptibility to infection, which occur in diabetes as well.
The nonenzymatic reactions of acetyl-CoA and S-adenosyl methionine
have been studied by Paik and co-workers (31-32).

Although these

reactions were readily demonstrable in vitro, their contribution to the
numerous acetylation and methylation reactions which occur in vivo is
difficult to assess.
by

Rydberg

and

Of substantial interest is the recent observation

Lindahl

(33)

that

S-adenosyl-methionine

nonenzymatically methyl ate nucleotide residues.

can

Since the products of

these reactions are potentially mutagenic, even a yery low frequency of
nonenzymatic methylation could have a profound biological effect.

For my thesis studies, I have investigated two novel aspects of
nonenzymatic addition reactions.

The first aspect (Chapters 2-4) pursues

the hypothesis that certain ketolic steroids, that is steroids bearing an
unhindered hydroxylcarbonyl function, can form covalent addition products
with the primary amino groups of proteins.

These steroids include

16a-hydroxyestrone and the glucocorticoids, exemplified in Figure 2 by
Cortisol.

These steroids were selected for study because elevated levels

of these molecules are associated with clinical syndromes.

The first.
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H2C-OH
'lOH

IlOH

6a -hy(jroxyestrone

Figure 2.

Cortisol
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16a-hydroxyestrone, is the product of the hydroxylation of estrone and is
an intermediate in the formation of estriol.

Both men and women with the

autoimmune disease, systemic lupus erythematosus, have been observed to
have an increased rate of 16-hydroxylation (34) and an increased urinary
level of 16a-hydroxyestrone

(35). The second steroid, Cortisol, is a

glucocorticoid and the long-term, therpeutic administration of these
steroids produces a variety of toxic effects (36). The formation of
cataracts for example, is observed in nearly all patients with rheumatoid
arthritis who receive 20 mg of prednisone per day for four years (37).
It could be reasoned that lens proteins might be susceptible to
nonenzymatic modification by glucocorticoids, in analogy to glucose and
cyanate which react with the lysine residues in lens crystallins and
facilitate the formation of high-molecular weight, refractile aggregates.
The studies to be described were undertaken with the goal of
demonstrating that the diverse pathological sequelae of autoimmunity or
drug toxicity might be attributed to a common mechanism, i.e. protein
modification.

In the next chapter, model reactions between albumin and

these two steroids are described.
vivo

studies

linking

steroid-induced

Chapter 3 presents in vitro and in

glucocorticoid-lens

cataracts.

Chapter

4

protein

describes

adducts

the

with

reaction

of

16a-hydroxyestrone with membrane proteins and the detection of these
addition products in patients with systemic lupus erythematosus.

Studies

on the occurence of anti-estrogen antibodies are also presented.
The

second

aspect

of

nonenzymatic

reactions

which

I have

investigated are in vitro studies demonstrating the nonenzymatic
modification of DNA by reducing sugars.

Evidence for the occurence of

protein-bound Maillard products on long-lived structural proteins led to
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the hypothesis that similar products may accumulate on nucleic acids.
Since nucleic acids are also long-lived molecules in the resting cell,
the accumulation of glucose-derived DNA adducts may lead to abnormalities
in DNA function.

Many current theories of aging emphasize the concept

that the functional decrements characteristic of cellular senescence are
due to the progressive accumulation of unrepaired genetic lesions.
122).

(121,

The long-term modification of DNA by reducing sugars could be a

mechanism for the decreased genetic viability and increased tumorigenesis
observed

in the aged

organism.

Chapter 5 describes

experiments

demonstrating that DNA and nucleotides can react with reducing sugars in
vi tro to form fluorescent Maillard products.

In a model prokaryotic

system, DNA molecules are inactivated and mutagenized by incubation with
a reducing sugar.
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2.

Nonenzymatic Reactions of 16a-Hydroxyestrone and Cortisol
with Proteins In Vitro.

12.

A.

Model studies of the nonenzymatic modification of albumin.

The ability of two ketolic steroids, 16a-hydroxyestrone and
Cortisol, to form covalent adducts with
investigated.

human serum albumin was

We hypothesized that the presence of the carbonyl moiety

would permit these steroids to form freely reversible Schiff base
intermediates with the amino groups of proteins.

The adjacent hydroxyl

group then would allow a Heyns rearrangement (38) to occur, resulting in
a stable ketoamine adduct with the protein.

Figure 3 shows this proposed

reaction scheme for the estrogen metabolite 16a-hydroxyestrone.

In this

case, the Schiff base would form at the C-17 carbonyl and a rearrangement
involving the C-16 hydroxyl could occur through the D-ring of the
steroid.

In the case of the glucocorticoid Cortisol (Fig. 4 ) , the

reaction would be analogous to the reaction of a ketose with protein
amino groups in that the Schiff base and subsequent Heyns rearrangement
would occur at the C-17 dihydroxyacetone side chain. The following
chapter

describes

model

studies

of

the

reaction

between

16a-[6,7-3H]hydroxyestrone and [1,2-3H]cortisol and human serum albumin.

Methods
Reagents.

16a-[6,7-3H]Hydroxyestrone (50 Ci/mmol; 1 Ci = 3.7 x 10^0

bequerels) was synthesized by the procedure of S. Ikegawa and J. Fishman
(39).

This material was stored in toluene/ethanol, 9:1 (v/v) at -80°.

[2,4,6,7-3H]Estrone (80 Ci/mmol) and [1,2-3H]cortisol

(47 Ci/mmol) were

obtained from Amersham and stored at -80°. Radiochemical purity was
monitored by HPLC as described below.

The steroids were acetylated prior

to chromatography by incubating with pyridine containing 10% (v/v) acetic
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Protein

\

.y^-^
NH,

' Lysine t-amine

i6aOHE

AOditiOn Product

-H,0

IlOH

HO

Schiff Base

LQ

Heyns
Protein

n
Figure 3. The reaction scheme between 16a-hydroxyestrone and
the e-amino group of lysine residues, showing the adducts formed
by the Heyns rearrangement and by reduction with NaCNBH^.
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c=o

Protein

HOv^.'-vjAliOH

-INH,
Cortisol

'' Lysine E-amino

H5C-OH
HO-C-NH^

• Protein

HOV.^-VJA'IOH

Addition Produd

-H,0
H2C-OH
'Protein

Heyns

y^

Schiff Base

NaCNBH.

/
HC=0
I
HC-vNH'
•lOH

•Protein

H5C-OH
HC'/'NH'
lOH

'Protein

Figure 4. The reaction scheme between Cortisol and the
e-amino group of lysine residues, showing the adducts formed
by the Heyns rearrangement and by reduction with NaCNBH,.
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anhydride.
Human serum albumin (not defatted) was purchased from Sigma and used
without further purification.
Albumin/Steroid Incubations.

One hundred and thirty picomoles of

either 16a-[3H]hydroxyestrone, [^Hjestrone, or [^Hjcortisol was placed
into microfuge tubes and evaporated under nitrogen.

The steroids were

dissolved in 60 ul ethanol, followed by the addition of 0.54 ml of 50 mM
potassium phosphate buffer, pH 7.4/10% (v/v) ethanol.

The final

incubation mixture contained 0.13 uM steroid and 40 mg of albumin per
ml.

For experiments

contained

requiring

reducing conditions, the mixtures

in addition 15 umol of sodium cyanborohydride

(NaCNBH3;

Sigma)(40).

At time zero, the mixtures were transferred from 0° to a 37°

water bath.

At indicated times, 0.1 ml aliquots were removed, placed

inside dialysis tubing (M^ cutoff, 12,000-14,000) and dialyzed for 24 hr
against 2 liters of 50 mM potassium phosphate, pH 7.4/10% ethanol.

The

remaining unreacted steroid was removed by chromatography over a column
(1 x 29 cm) of Sephadex G-lOO (Pharmacia), which was equilibrated with 50
mM potassium phosphate buffer, pH 7.4/10% ethanol.

The flow rate was 3

ml/hr, and the protein eluate was monitored by absorbance at 280 nm with
a Uvicord II (LKB Instruments).

Fractions (0.5 ml) were collected, added

to 6.0 ml of Hydrofluor (National Diagnostics, Sommerville, N.J.), and
the amount of radioactivity was determined with a Packard Tricarb
scintillation counter.
Albumin Acetylation.

A 200 mM solution of acetylsalicylic acid

(Malinckrodt) was prepared in 1 ml of 50 mM potassium phosphate (pH 7.4)
and the pH was adjusted to 7.4 with 15-20 yl of 45% (w/v) potassium
hydroxide.

A portion (0.1 ml) of this solution then was added to 0.1 ml
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of a human serum albumin solution (100 mg/ml) dissolved in 50 mM
potassium phosphate, pH 7.4/10% ethanol and incubated at 37^. At the end
of 10 hr this material was dialyzed against 2 liters of 50 mM potassium
phosphate, pH 7.4/10% ethanol to remove unreacted acetylsalicylic acid.
A control
performed.

incubation containing no acetylsalicylic acid was also
The acetylated and control albumins (2.5 mg each) were then

incubated for 42 hr with 18 umol of the ^H-labeled steroid in a volume of
62 ul and assayed for binding as described above.

The experiment that

measured reducible bonds contained in addition, 1 umol of NaCNBH3.
Adduct Characterization.

Albumin which had been treated with 16a-

[^Hjhydroxyestrone in the presence of NaCNBH3 for 48 hr was dialyzed
against 50 mM potassium phosphate, pH 7.4/10% ethanol to remove free
steroid.

The protein (4 mg) was subjected to acid hydrolysis by adding 2

ml of 6M HCL in a tube that was sealed and evacuated and incubating the
mixture at 110° for 8 hr (41). At the end of this time, the acid was
evaporated under nitrogen.

The hydrolysate was acetylated for HPLC

analysis by dissolving the residue in 1 ml of pyridine (distilled under
N2 and stored over NaOH pellets) and adding 0.1 ml of acetic anhydride.
After an incubation at 80° for 30 min, the solvent was evaporated under
nitrogen.

This material was dissolved in 0.4 ml of 5 mM sodium

phosphate, pH 7.4/50% methanol and subjected to HPLC analysis.
A 16a-[3H]hydroxyestrone-lysine adduct was prepared as a standard.
A 50 ul solution of 50 mM N-a-t-butoxycarbonyl lysine (Vega Biochemicals,
Tucson AZ.) dissolved in either 100 mM sodium phosphate, pH 7.4/10%
ethanol or in 100 methanol, was incubated with 0.8 um 16a-[3H]hydroxyestrone and 20 mM NaCNBH3 for 6 days at 370. Aliquots (2 or 3 ul) were
removed at intervals.

The aqueous solutions were diluted 1:5 and
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extracted 3 times
steroid.

with 3 volumes of ether to remove the unreacted

After drying the sample under nitrogen, the a-blocking group

was removed by incubation with either 50 ul of 4 M HCL or 50 ul of a
solution of 50% trifluoroacetic acid in methylene chloride for 20 min
at 25° (42). The acid was evaporated under nitrogen, and the products
were acetylated by incubating for 30 min at 80^ in 0.1 ml of dry
distilled pyridine containing 10% acetic anhydride. This solution was
then evaporated under nitrogen, and the residue was dissolved in 0.4ml of
BwiA sodium phosphate, pH 7.4/50% methanol.

The identity of the standard

was validated by its predicted chromatographic behavior after removal of
the blocking group and by the increased retention time observed when the
standard was run in a solvent system containing 1% acetic acid instead of
neutral buffer.
HPLC analysis.

All HPLC studies were performed on a reverse-phase

Waters Associates C]3 uBondapak column in a Hewlett-Packard 1084B liquid
chromatograph

interfaced with a Flo-One radioactive flow detector

(Radiomatic Instruments and Chemical, Tampa, FL). Sample (30-60 ul) was
injected into a mobile phase of 10 mM sodium phosphate, pH 7.4/50%
methanol, which increased linearly to 100% methanol from 0 to 55 min.
The flow rate was 1 ml/min.

The column eluate was mixed with

scintillation fluor (Flo-Scint II); Radiomatic, Tampa, FL) which flowed
at a rate of 3 ml/min.

The Flo-One microprocessor integrated the amount

of radioactivity eluted.
Peptide Mapping.

Tryptic peptides were prepared from albumin which

had been extensively modified by incubation for 8 days with 3.45 mM
steroid supplemented with either 1.26xlo6cpm of [3H]16a-hydroxyestrone or
9.00xl06 cpm of [^Hjcortisol.

The reduced incubation contained 20 mM

18.

NaCNBH3.

After extensive dialysis the modified proteins were purified by

gel filtration chromatography as described above.
of

incorporation

16.9xlo3cpm/mg

was

for

6.9xlo3cpm/mg

for

The specific activity

16a-hydroxyestrone-HSA,

16a-hydroxyestrone-HSA

(NaCNBH3

reduced),

36.0x1O^cpm/mg for cortisol-HSA, and 75.2x1O^cpm/mg for cortisol-HSA
(NaCNBH3 reduced).

The proteins were lyophilized and redisolved in 10 ml

of a solution of 6M Gn-HCL and 1 M Tris-HCL, pH 8.8.

Disulfide bonds

were reduced by adding 25 mg of dithiothreitol and incubating at room
temperature for 4 hours under nitrogen.

Reduced proteins were then

aminoethyl ated (43) as follows. A 680 mg/ml of N-(3-Iodoethyl)triflouroacetamide (Aminoethyl-8, Pierce Chemical Co. Rockford, II.) was
prepared in methanol and 0.56 ml added to the protein solution.

This was

incubated at 50° for 1 hour, after which another 0.50 ml of Aminoethyl-8
was added and incubation continued for an additional 3 hours.

The

reaction was terminated by the addition of 0.75 ml of 2 N acetic acid and
dialyzed against several changes of 2 liters of 5 mM acetic acid.
After lyophilization, the aminoethyl ated proteins were redisolved in
2 ml of 0.5

NH4CO3 (pH 8.8) and enzymatically hydrolyzed by the addition

of 0.27 ml of a 180 U/ml solution (prepared in 0.55 NH4CO3) of trypsin
(TPCK treated, Worthington, Freehold, NJ). The digestion was allowed to
proceed for 2 hours at 37°, after which the solution was heated to 100°
for 5 minutes and cooled.

The digestion was repeated two more times.

The digest was then lyophilized and the peptides resuspended in 2 ml of
0.1% phosphoric acid.

Insoluble material was removed by centrifugation.

Of the total radioactivity, 82.0% was found to be present within the
soluble peptides.
Peptide mapping was performed by reverse-phase HPLC (43) utilizing a
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Waters Associates C18 column.

Samples were injected into a mobile phase

consisting of 0.1% phosphoric acid/2% acetonitrile which increased
linearly to 50% acetonitrile from 0 to 40 min.
ml/min.

The flow rate was 1

Radioactivity analysis was conducted on 0.35 mg of peptides.

Six second fractions were collected, mixed with scintillation fluid, and
counted in a Beckman LS 7000 liquid scintillation spectrometer.

Results
Figure 5 shows that the incorporation of 16a-[3H]hydroxyestrone into
albumin increases with time in both the presence and the absence of
NaCNBH3.

In the presence of NaCNBH3, the rate of incorporation is rapid

and plateaus when 80% of the free steroid has reacted.
binds

efficiently

to

albumin,

most

likely

through

This steroid
hydrophobic

interactions, and forms reversible Schiff bases with available amino
groups.

These Schiff bases are chemically reduced by the cyanobrohydride

and are trapped as covalent adducts.

Under nonreducing conditions, the

coavalent attatchment af 16a-hydroxyestrone proceeds at a slower rate.
It is postulated that the presence of a hydroxyl group adjacent to the
C-17 carbonyl permits the initial Schiff base to undergo a Heyns
rearrangement and form a stable, covalent steroid-protein adduct.
To illustrate this point, albumin was incubated with L^Hjestrone,
which has a C-17 carbonyl moiety but lacks the 16a-hydroxyl group.

In

the presence of NaCNBH3, a significant amount of estrone is incorporated
into albumin, indicating that the 17-carbonyl

of estrone forms a

transient Schiff base adduct that can be trapped by reduction.

However,

no estrone is incorporated in the absence of NaCNBH3 because the Schiff
base cannot undergo a Heyns rearrangement.
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Figure 5. Incorporation of 16a-hydroxyestr6ne and estrone into
albumin, under reducing (o) and nonreducing conditions (§).
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The ability of Cortisol to form adducts with albumin also was
examined.
C-20.

Cortisol possesses two carbonyl groups, one at C-3 and one at

We hypothesized that a Schiff base involving the C-20 carbonyl

could readily undergo a Heyns rearrangement with the unhindered C-21
hydroxyl.

The formation of cortisol-albumin adducts in both the presence

and the absence of NaCNBHs is shown in Figure 6.

The presence of NaCNBH3

increases the rate of Cortisol incorporation only slightly.

It would

appear that the Heyns rearrangement is so rapid that the formation of the
Schiff base is rate-limiting for this reaction.

The great reactivity of

the Cortisol side chain is well recognized and is exemplified by its
spontaneous rearrangement and degradation to acidic products (45).
Previous studies of the nonenzymatic glycosylation of albumin
suggested that the Schiff base adduct probably involves the e-amino goups
of lysine residues (46). In order to determine whether 16a-hydroxyestrone and Cortisol also react at this position, albumin was first
acetylated with acetylsalicylic acid, which modifies the lysine located
at position 199 of the amino acid sequence of human albumin (47). The
acetylated albumin was then incubated with steroid.
significant decrease in the formation

There was a

of steroid adducts with acetylated

albumin, thus indicating a significant competition for this reactive
lysine residue (Figure 7 ) .
The 16a-hydroxyestrone-albumin adduct, after reduction with NaCNBH3,
was subjected to acid hydrolysis.

The hydrolysate was acetylated and

analyzed with HPLC utilizing a reverse-phase column.

A prominent peak

was observed to elute at 8-9 minutes, which was followed by the elution
of several peaks together at 19-23 minutes (Figure 8 ) . The latter peaks
correspond to unreacted 16a-hydroxyestrone and products produced by the
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reduction and acid hydrolysis of this steroid.

The first peak was

observed to coelute with a synthetic 16a-hydroxyestrone-lysine adduct
standard.

These

data

indicate

that

16a-hydroxyestrone

forms an

acid-stable adduct with the e-amino group of lysine when Incubated with
albumin under reducing conditions.

An elution profile identical to

Figure 8 was obtained after the acid hydrolysis of albumin which had been
incubated with 16a-hydroxyestrone and reduced with NaBL2HJ4 (data not
shown).
Chromatography of an acid hydrolysate of 16a-hydroxyestrone adducts
prepared without NaCNBH3 failed to show a significant peak near the 8-9
minute position.

Evidently, the ketoamine Heyns product is destroyed by

acid hydrolysis, whereas the a-hydroxyamine product produced by NaCNBH3
reduction is not.
Figure 9-12 show the reverse-phase HPLC elution pattern of tryptic
peptides prepared from steroid modified albumin.
shown, corresponding

to albumin modified

Four peptide maps are

by 16a-hydroxyestrone

Cortisol either in the presence or the absence of NaCNBH3.

or

These prepa-

rations were substituted at a molar ratio of steroid to albumin of 2.1:1
for

16a-hydroxyestrone-HSA,

16a-hydroxyestrone-HSA
(NaCNBH3 reduced).

2:1

for

cortisol-HSA,

(NaCNBH3 reduced) and 3.6:1

5.1:1

for

for cortisol-HSA

From these peptide elution patterns it is apparent

that both 16a-hydroxyestrone and Cortisol react at discrete sites in the
albumin molecule.

Two well resolved albumin peptides are labelled by

16a-hydroxyestrone in the absence of NaCNBH3.

Cortisol appears to label

3 to 5 major peptides, although 3 of these elute wery close together in
the chromatogram.

This poorly resolved triplet may in fact represent

peptides which are incompletely digested by trypsin.

Digestion may be
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Figure 9. Reverse-phase HPLC tryptic map of 16a-hydroxyestrone
modified albumin.

27.

Q.
O

400

Figure 10. Reverse-phase HPLC tryptic map of Cortisol modified
albumin.

28.

Figure 11. Reverse-phase HPLC tryptic map of albumin modified by
I6a-hydroxyestrone in the presence of NaCNBH^-

29.

Figure 12. Reverse-phase HPLC tryptic map of albumin modified by
Cortisol in the presence of NaCNBH^.
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inhibited by the presence of the Cortisol moiety; in analogy to the
observation that glycosylated lysine residues are poor substrates for
proteolytic enzymes (47).
Inclusion of NaCNBH3 in the incubation mixtures was found to lead to
the modification of additional albumin sites.

These lysine residues can

readily form Schiff bases with the steroid carbonyl groups, but under
normal conditions; i.e. in the absence of NaCNBH3, stable rearrangement
products do not form.

This may be the result of factors in the

micro-environment of a particular lysine residue.

Important factors might

be the presence of an adjacent hydrophobic binding site to orient the
steroid, or the ability of nearby amino acids to assist in the proton
transfer reaction which produces the Heyns rearrangement.
Although the Schiff base rearrangement products between sugars and
amino acids are stable, there is in fact a yery slow reversal rate.

In

order to estimate the reversal rate for the steroid-albumin rearrangement
products, albumin was modified with 16a-[3H]hydroxyestrone or [^Hjcortisol
and dialyzed at 370C for several months against a buffer containing 50 mM
potassium phosphate, pH 7.4 and 10% ethanol.
Figure 13 illustrates the results of these experiments.
control experiments are also shown.

Two relevant

The first shows that [^H]steroids

which were reacted with albumin in the presence of NaCNBH3 are stable and
not dialyzable for at least a 70 day period.

The second control

demonstrates that when these steroids are added to albumin immediately
prior to dialysis, greater than 95% of the radioactivity can be recovered
in the dialysate within 24 hours.

Thus, once the steroid-protein linkage

has reversed, the steroid is freely dialyzable and will not reassociate
with the albumin via hydrophobic or other interactions.

The results of
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Figure 13. Measurement of the off-rate of steroid-albumin adducts.
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these studies indicate that only a portion of the steroid ligands are
reversible.

In the case of 16a-hydroxyestrone, this amount represents

about 50% of the protein bound radioactivity; and in the case of Cortisol,
about 30%.

These observations may be accounted for by either of two

mechanisms.

One possibility is that during the long time course of this

experiment further reactions - such as an oxidation - may occur, producing
a steroid-protein adduct which is chemically irreversible.

In the case of

the cortisol-lysine Heyns product, this could easily occur by oxidation of
the C-21 aldehyde to a carboxylic acid.

Another possibility is that some

of the reactive albumin sites lead to the formation of Heyns products
which are in fact irreversible.

For example, these sites may be

inaccessible to the water molecule which hydrolyzes the Schiff base and
reverses the addition reaction.
The half life of the rapidly reversing steroid - lysine adduct was
calculated from the linear part of the decay slope and found to be 26.3
days for 16a-hydroxyestrone-HSA and 24.4 days for cortisol-HSA.

It is possible to calculate the rate constants for the formation of
the steroid-protein adducts.

Reactions involving Schiff bases and their

rearrangement products can be written in the following scheme.

[S] + [A3 > ^..[S=A3 ^[S-A]
fast

slow

where [S] and [A] are the concentration of free steroid and free albumin
respectively, [S=:A] is the concentration of the Schiff base intermediate,
and [S-A] is the concentration of the Schiff base rearrangement product.
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In a kinetic form, this becomes:

[S] + [A].,''^ -[S=A3 • >^^ • [S-A] (A)
k_i

K_2

The rate at which albumin forms the Schiff base linkage (k]) can be
calculated from conditions in which all of the adduct is trapped and the
reverse reaction (k_-|) cannot occur.

These conditions are satisfied in

the incubations which contain an excess of NaCNBH3. From the linear slope
of the incorporation curves (Figs. 5 and 6 ) , k] can be readily calculated
from:
d[S=A] = ki[S][A]dt (B)
Note that k] is the overall rate constant for the condensation of the
steroid at the multiple sites within albumin and,
h

= (kla ^ h b ^ ...)[S][A]

where k]a, k-jb, etc. are the rates of condensation for each reactive
lysine residue.
Therefore,

k]

_ d[S=A] ^
dt

_J
[S][A]

Under the experimental conditions for 16a-hydroxyestrone,
[A] = 601.3 uM, [S] = 0.13 uM, [S=A] = .061 uM and t=6 hr.
Therefore,
k] =131 ^ 10"^ nM"^ hr-1 for 16a-hydroxyestrone.
Similarly for Cortisol,
where [S=A] = .045 uM at 48 hr.
k] = 12 X 10-3 nM-"l hr'^ for Cortisol.

(C)
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The overall rate (kobs.^ ^^^ ^^^ formation of a stable rearrangement
product can be calculated from reactions performed in the absence of
NaCNBH3.

Under the reaction conditions described for Figure 4, albumin

amino groups are present in large excess and equation (A) can be
represented by the pseudo first-order expression:

[S] J^obsi^L^ [S-A] (D)

In the case of the reaction between 16a-hydroxyestrone and albumin
kobs^A] = k2 since k 2 « k-| (Fig. 4) and k2»k_2 (Fig. 13). k2 can be
calculated from the amount of incorporation at 48 hours, where the rate is
still linear.
Therefore:

k2 = 0.0021 hr-^

for 16a-hydroxyestrone.

It is interesting to compare these values to those calculated for the
Amadori reaction between glucose and hemoglobin (48). In this case, the
rate of Schiff base formation was found to be: 0.3 x 10-3 mM"^ hr-^,
and the rate of the Amadori rearrangement is

.0055 hr-^.

Therefore, the rate of Schiff base formation for 16a-hydroxestrone with
albumin is 2300x slower than for glucose with hemoglobin; and the rate of
the Heyns rearrangement is about 2.6x slower.
These rate values probably represent overestimates since the in vivo
rate of reaction may be slower then that measured in vitro.

For the

Amadori product between albumin and glucose for example, the in vivo rate
is slower by about 60% and may be due to competition between glucose and
other ligands (49).
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B.

Structural analysis of steroid-lysine adducts.

Structural studies of sterold-adducts were performed on model
compounds prepared by the incubation of either 16a-hydroxyestrone (16aOHE)
or Cortisol with lysine derivatives blocked in the N-a-position. The
following section describes the synthesis of these model steroid-lysine
addition products and the elucidation of their structure.

Methods
Synthesis of N«-acetyl, N^-acetyl, Ng-(3,16a-d1acetyl-l,3,5(10)estratrien-17-yl )-lysine.
L-lysine

(Vega

A 1 ml solution containing 450 mM N-a-t-Boc-

Chemicals, Tuscon,

Az.), 34 mM

16a-hydroxyestrone

(Steraloids, Wilton, N.H.), and 86 mM NaCNBH3 (Sigma Chemical Co.) was
prepared in methanol/pyridine
supplemented

(3:1 v/v).

A parallel

incubation was

with 1 uCi of 16a-L6,7-3Hjhydroxyestrone.

incubated at 370.

These were

At daily intervals, 25 ul aliquots were withdrawn and

the reaction products analyzed by reverse-phase HPLC as described on page
17.

At the end of 8 days the entire mixture (0.8 ml) was removed, the

solvent evaporated under a stream of N2 and the t-Boc group removed by
adding 1 ml of a 50% mixture of trifluoroacetic acid and methylene
chloride (42). This was Incubated at room temperature for 20 min.

The

solvent then was evaporated and the products acetylated by adding 0.5 ml
of pyridine and 0.05 ml of acetic acid anhydride and incubating at 80° for
30 minutes.
redissolved

The solvent was then evaporated under N2 and the residue
in 1 ml methanol.

Insoluble material

was removed by

centrifugation and the supernatant stored at -20° prior to purification.
0.1 ml aliquots were purified by reverse phase HPLC (p. 17) and the peak
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fractions containing 16a-hydroxestrone-lysine pooled.
was isolated.

0.57 mg of product

This corresponds to a yield of 5.2%, based on the amount of

16aOHE starting material.
Synthesis of N"-(9-fluorenylmethyloxycarbonyl), Ng-(20-cyano-3-oxo11,17a,21-trihydroxy-4-pregnen-20-yl)-lysine.
100 mM Cortisol
Torrance, CA)

A 2 ml solution containing

(Steraloids), 54 mM N-a-Fmoc-L-lysine

(Bachem, Inc.

and 54 mM NaCNBH3 was prepared in a buffer containing 25 mM

potassium phosphate pH 7.4, 25% methanol and 25% pyridine.
solution was prepared which was supplemented with 1 uCi of
cortisol.

A second

[1,2-3H]-

These solutions were incubated at 37° for 6 days.

On days 2

and 4 an additional 54 mmoles of NaCNBH3 was added to inhibit the
formation of brown products.

At the end of six days, 1.6 ml of each

incubation was removed and diluted with 1.6 ml of methanol.

The reaction

mixtures were analyzed by reverse phase HPLC utilizing a Waters Associates
C-18 column.

Products were monitored by absorbance at 300 nm.

The

solvent system consisted of a gradient of 5 mM sodium phosphate, pH 7.4
and methanol which increased linearly from 40% to 80% methanol from 0 to
25 minutes.

Two addition products (peaks I and II, Fig. 15) were

identified and isolated by injecting, repetitively, 200 ul of the
incubation mixture.

1.73 mg of peak II was isolated, corresponding to a

yield of 1.5% (based on Cortisol starting material).
Analysis.

Absorption spectra were recorded on a Hewlett Packard

8450A spectrophotometer.

For mass-spectroscopy, 50 to TOO ug of each

sample was desalted by reverse-phase HPLC utilizing a C-18 column and
gradient elution with water-methanol.
spectra were obtained

Fission fragment ionization mass

on the Rockefeller

time-of-flight mass spectrometer (51).

University

custom

built

Chemical ionization experiments
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were made with a VG 70-250 (Altringham, U.K.) double focusing magnetic
sector instrument and the desorption chemical ionization probe for sample
introduction.
Proton NMR spectra were recorded in methanol-2H4, Me2S0-2H6, and
Me2S0-2H6/chloroform-2H3

(2/1, v/v).

A Nicolet NTC-300

(wide-bore)

spectrometer was operated at 300 MH2 in the Fourier transform mode.
Chemical shifts are in ppm down field from tetramethylsilane.

Results
The incubation of 16a0HE with N-a-t-BOC-lysine and NaCNBH3 was found
to lead to the production of a single polar product which eluted yery
early in a reverse-phase HPLC system.

On the basis of UV absorbance and

the incorporation of [3H]16aOHE, this product was suspected to contain the
major structural elements of 16aOHE.
standard

de-blocking conditions

Treatment of the product with

decreased

its HPLC retention

suggesting the incorporation of N-a-t-Boc lysine .
de-blocked

product

co-chromatographed

with

both

time,

Furthermore, the

the

radioactive

acid-hydrolysis product of [3H]16aOHE modified albumin which had been
reduced with NaCNBH3, and with 16aOHE modified albumin which had been
reduced with NaB[3H]4 (data not shown).
Approximately 0.5 mg of the 16aOHE addition product was isolated by
repetitive purification on HPLC.

Figure 14 shows the proton NMR spectrum

of the acetylated 16aOHE addition product recorded in methanol-2H4.

A

portion of a spectrum recorded in Me2S0-2H6 is shown in order to more
clearly demonstrate the resonances of the C-16H^, the C-17h[, and the amide
N-H^ of the lysine side chain.

The application of shielding constant

calculations to reference spectra of 16aOHE-diacetate and estrone acetate
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indicated that in the proposed structure in Fig. 14, the 16-CIH proton
should appear in the 4.0 to 4.5 ppm region.

We assign the peaks at 4.4

and 4.05 ppm (methanol-2H4) as the 16-CH^ resonances of the 1 7 - B and 17-a
side chain epimers, respectively (these peaks appear at 4.35 and 3.9 ppm
in the Me2S0-2H5 spectrum).

By comparison to reference spectra of

N-acetyl lysine, the larger peak between them (4.3 ppm in methanol-2H4,
4.15 ppm in Me2S0-2H6) is the lysyl a-Ch[.

The two NMR peaks in the 5.5

ppm region (methanol-2H4) are assigned as amide rotamers and are more
clearly defined in the non-exchanging solvent Me2S0-2H5.

The peaks

assigned to 17-CF[ appear at 3.4 and 3.5 ppm in Me2S0-2H6 for the a- and Bside chain epimers, respectively; these peaks both appear as partly
resolved doublets, as would be expected for the 17-C]1, coupled only to
16-CH^.

The 16-CjH peaks are broader, reflecting more complex coupling to

both 17-CH^ and IS-CH^.

These data are consistent with the e-lysyl amide

linkage being at C-17 of the estrogen nucleus and not at an alternative
site, such as C-16.
assignment

of

this

The overall
product

as

spectrum is consistent with the
the

tetra-acetyl

derivative

N^-(3,16a-dihydroxy-l ,3,5(10)-estratrien-17-yl)lysine.

of

The presence of

two stereoisomers at the C-17 position indicates that NaCNBH3 reduces the
initial Schiff base to produce both a- and 6-17-lysyl epimers.
Initial attempts to synthesize a cortisol-lysine adduct were hampered
by the tendency of these reactions to undergo nonenzymatic browning and
yield a complex mixture of fluorescent products.

Supplementing these

incubations with a large excess of NaCNBH3 inhibited the formation of
brown products.

The use of the N-a-Fmoc-lysine derivative (52) enabled us

to monitor reaction products by absorbance at 300 nm.

Cortisol absorbs

weakly at this wavelength and Fmoc containing products are readily
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Proton nuclear magnetic resonance spectra of the
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10
12
Elution (ml)

Figure 15. Reverse-phase HPLC elution profile of a 6 day incubation
mixture of N-a-Fmoc-lysine, Cortisol, [ H]cortisol, and NaCNBH^.
A = Cortisol, B = N-a-Fmoc-lysine, C = free Fmoc. Peaks I and II
designate the major Cortisol-N-a-Fmoc-lysine addition products.
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identified.

Figure 15 shows the HPLC elution profile of an incubation

mixture which

had been supplemented with [3H]cortisol.

The peaks

designated A,B, and C correspond to Cortisol, N-a-Fmoc-lysine, and fmoc
respectively.

From the ratio of the tritium content and the extinction at

300 nm, it is apparent that there are two cortisol-lysine conjugates
(designated peaks I and II).

Analysis of absorbance spectra also

confirmed that peaks I and II contained equimolar amounts of Cortisol and
N-a-Fmoc-lysine (data not shown).
Figure 16 shows the proton NMR spectrum of the peak II product.
Resonances were assigned by comparison to reference spectra of Cortisol
and N-a-Fmoc-lysine recorded under analogous conditions.

It is apparent

that the peak II conjugate contains an intact Cortisol and N-a-Fmoc-lysine
residue linked in the Cortisol C-17 side-chain.

The absence of a C-20

proton and the similarity of the C-21 proton resonances between Cortisol
and the lysine adduct was unexpected (Fig. 17), and suggested that the
structure might be an unreduced Schiff base at the C-20 position.

A

possible alternative structure, that of lysine linked at the C-21
position, was considered unlikely since the resulting a-amino ketone would
produce chemical shifts for the C-21 protons that are upfield from the
observed positions.
The positive fission fragment ionization spectrum of this product
contained a main ion of m/z 761.4 +^ 1.0.

This mass was taken to comprise

the M+Na)"*" ion for the cortisol-lysine product.

Because of the relatively

large error limits of this mass determination, a new synthesis of the Peak
II cortisol-lysine product was undertaken.

Additional NaCNBH3 was util-

ized in an attempt to increase yield and prevent side reactions.

Spectros-

copic analysis of this new preparation demonstrated that it was reduced
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ting the similar chemical shifts of the C-21 protons
in Cortisol (A) and the Peak II conjugate (B).
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at the position of the C-3 carbonyl.

A fission fragment ionization

spectrum of higher quality was obtained for this cortisol-lysine product,
and demonstrated an ion with m/z 764.2 +_ 0.2 (M+Na)"^.

In addition, the

negative fission fragment spectrum showed an ion of m/z 740.0 ^ 0.5 which
comprises the (M-H)- ion.

These results constitute strong evidence that

the molecular weight of the first preparation is 739 and that of the
second preparation is 741.

Each of these values is greater, by 25 mass

units, than a reduced cortisol-lysine Schiff base.
data and mechanistic

On the basis of these

considerations, we conclude that

adventitious

cyanide, generated from the breakdown of cyanoborohydride, had added to
the Schiff base intermediate to form a 20-cyano amine structure.
Figure 18 summarizes the reaction mechanism which led to this
isolated product.

A Schiff forms at the C-20 carbonyl.

constraints

the Cortisol

within

side

chain

cyanoborohydride from reducing the Schiff base.

most

likely

Steric
prevent

Cyanide is liberated by

the breakdown of cyanobobrohydride, and being a small nucleophile, readily
adds to to the C-20 position.

It is conceivable that the Schiff base is

partially stabilized by hydrogen bonding between the e-nitrogen and the
adjacent C-17 and C-21 hydroxyl groups.
NMR analysis of th Peak I cortisol-lysine product indicated that this
conjugate also was linked in the Cortisol side chain (data not shown).
Additional structural studies were hampered by the fact that this compound
underwent further reaction to form brown products.

By analogy to known

reactions between reducing sugars and amino acids (53), it seems likely
tha peak I is an unreduced product and that it is either a stable Schiff
base or the Heyns rearrangement product.

Both of these structures would

be expected to continue to react, forming brown, complex rearrangement
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Figure 18. Proposed reaction scheme leading to the
Peak II product (right), and the mechanism of the
Heyns rearrangement.
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products.
In conclusion, two model steroid-lysine conjugates have been
synthesized, isolated, and their structures determined.

Figure 19 shows

space-filling models of the reduced 16a-hydroxyestrone-lysine adduct and
the cortisol-lysine Heyns product.

The product formed from the reaction

of 16aOHE and lysine was found to have a structure predicted for a reduced
Schiff base between these two molecules.

A stable, Cortisol lysine

addition product was similarly synthesized and isolated.

This compound

was found to have an incorporated cyano moiety, produced by the
nucleophilic addition of a cyanide ion which is generated during the
course of the incubation.

The reaction between Cortisol and primary amino

groups differs from other Schiff base rearrangment reactions, such as
those involving 16a-hydroxyestrone or reducing sugars, in that the Schiff
base intermediate is not reducible with cyanoborohydride.

This would

account for the observation that the rate of Cortisol incorporation into
albumin is not accelerated by the presence of cyanoborohydride.
An interesting hypothesis emerged from these studies.

Previous work

has demonstrated that steroids which have glucocorticoid activity
invariably contain a ketol side-chain at the C-17 position of the steroid
nucleus.

It is possible that the side chain enables these steroids to

interact with the glucocorticoid receptor by forming a partially
stabilized Schiff base at the C-20 carbonyl.

Figure 19. Space-filling models of the
reduced 16a-hydroxyestrone-lysine adduc
(upper panel) and the cortisol-lysine
Heyns product (lower panel).
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3.

Nonenzymatic Modification of Lens Proteins by
Glucocorticoids in Steroid-Induced Cataracts.
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A.

Introduction.
The biological effects of glucocorticoids are diverse and widespread.

They influence protein, fat, and carbohydrate metabolism and electrolyte
and fluid balance.

In the human, the physiology of virtually every organ

system is influenced by these hormones (54).
Therapeutically,

glucocorticoids

are

administered

either

in

physiological doses to correct adrenal insufficiency or in pharmacological
doses to treat inflammatory conditions, collagen diseases, and certain
other disorders.

For many chronic diseases, they are often the last

course for the alleviation of severe inflammation.

It is also primarily

in these cases that the adverse affects of glucocorticoids become
apparent.

Common

immunosuppresion

manifestations

include

cataract

formation,

an

leading to an increased susceptibility to infection,

osteoporosis, a proximal myopathy, and behavioral

disturbances (36).

Perhaps one of the hallmarks of glucocorticoid toxicity is the development
of bilateral cataracts.

In 1960, Black et al. reported a high incidence

of posterior subcapsular cataracts in patients receiving moderately high
doses of corticosteroids
well-documented (56).

(55).

Since then, this phenomenon has been

For example, cataracts are observed in nearly all

patients who receive 20 mg of prednisone per day for four years for the
treatment of rheumatoid arthritis (37). The development of steroidinduced cataracts correlates well with the dosage and duration of therapy
and generally halts after the withdrawal of steroids (57).
A cataract is a partial to complete opacification of the lens of the
eye.

The opacity may be located on the surface of the lens or within the

crystalline material of the lens.

The location of the lens relative to

other structures in the eye is shown in Figure 20.

A cross-section of the
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lens, taken throught the equator is displayed in Figure 21.
capsule surrounds the lens.

A fibrous

The substance of the lens consists of highly

differentiated lens fiber cells which primarily contain the specialized
proteins called crystallins.

These cells have the highest protein content

of any tissue in the body, approximately 35% by weight (58). The cells
originate near the equator, grow and elongate into lens fibers, and
migrate toward the center of the lens.

The lens cells depend entirely on

the surrounding media, i.e. the aqueous and vitreous humors, for their
nutrient supply, oxygen, as well as for the removal of waste products.
The types of opacities induced by glucocorticoids are characteristic
because in initial stages, they always occur in the posterior subcapsular
region.
ties.

Other chemical agents also lead to posterior subcapsular opaciGrant's compendium: "Toxicology of the eye" lists the following as

inducing

these

types

of

changes:

bis-(phenylisopropyl)-piperazine,

busulfan, corticosteroids, dinitrophenol, dinitro-o-cresol, tripaparanol,
and cyanate (59).
posterior

Hyperglycemia, in addition, leads to cataracts of

subcapsular morphology.

Figure 21 shows that although

epithelial cells cover the anterior surface of the lens there are no
epithelial cells present on the posterior side.

The absence of an

epithelium is believed to make this region sensitive to opacification
since many agents might otherwise be removed or detoxified by the
epithelial cells.
A number of cataractogenic agents, specifically glucose, cyanate, and
busulfan have been shown to react with the amino groups of proteins to
form covalent-addition products.

Glucose and cyanate in particular, have

been shown to modify the lysine residues of lens proteins, inducing
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Fiqure 20. A schematic cross-section of the eye, showing
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Figure 21. Schematic cross-section of the lens taken
through the equator.
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sulphydryl oxidation, and the formation of light-scattering aggregates
(16, 60). On the basis of these observations, it seemed reasonable to
pursue the hypothesis that glucocorticoid modification of lens proteins
might be involved in the induction of lens opacification.

The following

chapter describes the development of two experimental models for the
steroid-induced cataract, the detection of the glucocorticoid adducts in
human steroid-induced cataracts, and studies of the effect of
gluccorticoids on lens crystallins in vitro.
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B.

Glucocorticoid-lens protein adducts in two experimental models of
the steroid-induced cataract.

Investigations into the pathogenesis of the steroid cataract have
been hampered by the lack of suitable experimental models for the
induction of these lesions.

In vivo, both the rat and the chick appear to

be resistant to the cataractogenic effect of glucocorticoids (61, 62)
although a potentiating effect for the experimental dinitrophenol and
galactosemic cataract does occur (63, 64). There have been two reports of
long-term glucocorticoid therapy producing lens changes in the rabbit.

In

one study (65), the effects were cortical and anterior subcapsular while
in another (66), posterior subcapsular changes were described, but only in
rabbits which had simultaneously developed diabetes.

Recently, Nishigori

et al.(67) have described the induction of perinuclear opacities by
glucocorticoids in the developing chick embryo.

Chick lenses cultured in

in the presence of glucocorticoids show opacification (68), but these
experiments utilized very high concentrations (1 mM) of prednisolone.
The following section describes two models for the steroid-induced
cataract.

The first is an in vitro model utilizing the rat lens cultured

with low concentrations of prednisolone.
developed in the rabbit.

The second is an in vivo model

In this animal model, specific posterior

subcapsular opacities were induced by injecting glucocorticoids directly
into the vitreous chamber of the eye.

Methods
Reagents and Animals.
(Wilton, N.H.).

Steroids were purchased from Steraloids

[l,2,6,7-3H]Cortisol

(80 Curies/mmol, ICi = 3.7 x 10^0
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becquerels), [1,2,4,6,7-3H]dexamethasone (77 Curies/mmol), and

[2,4,6,7,-

3H]prednisolone (57 Curies/mmol) were obtained from Amersham (Arlington
Heights, II).

Radiochemical

purity was assessed by chromatography on

reverse phase HPLC as described earlier (p.l7).

Male Sprague-Dawley rats

(70-90 g) and young (4-6 wk) female New Zealand White rabbits were
obtained from Taconic Farms (Germantown, NY). Outbred rabbits of the same
sex and age were obtained from a local vendor.
Lens Culture.

Rat lenses were excised and washed at room temperature

with Medium 199 (Gibco, Grand Island, NY) supplemented with 5% heat
inactivated fetal bovine serum, 100 U/ml penicillin G, and 25 yg/ml
amphotericin B.

Lenses were cultured on wire grids (69) in 1 x 3.5 cm

tissue culture wells in Medium 199 containing S% heat-inactivated fetal
calf serum and 100 U/ml penicillin G.

Each well contained 2-3 lenses.

Incubation was at 37** in a humidified incubator containing an atmosphere
of 5% CO2 and balance air.
Glucocorticoids

were dissolved

in culture media containing

10%

ethanol and 3 ul added to each well, yielding a final concentration of
0.01% ethanol

and either 5 to 50 nM glucocorticoid or 35 uCi/ml

[2H]prednisolone (a final concentration of 5 nM). Control medium used
in the steroid-free incubations contained 0.01% ethanol as well.
medium was replaced on alternate days.

Culture

Reverse phase HPLC analysis of

the culture media after 48 hr of incubation demonstrated that less than
4% of the added [2H]prednisolone had undergone conversion to other
compounds.
Fractionation of lens proteins.

Lens proteins were fractionated with

modifications of the procedure described by Kramps, et al. (70). Three
rat lenses or a single rabbit lens was placed in an ice-cold glass tissue
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homogenizer which contained 1-2 ml of 0.1 M Tris-HCl buffer, pH 7.4 and
0.02% NaN3. The lenses were homogenized under a nitrogen stream with 8
strokes of a ground glass pestle.

The mixture was centrifuged at 20,000 x

g for 30 min at 4", and the supernatant solution (water-soluble fraction)
stored at 4° under nitrogen.

The sediment was resuspended in 10 ml of 0.1

M Tris-HCl buffer (pH 7.4), centrifuged again, and the supernatant
removed.

The washed sediment was then resuspended in 1.5 ml of 0.1 M

Tris-HCl buffer (pH 7.4), containing 7 M urea and 0.02% NaN3.

This

material was vortexed at intervals and allowed to stand for 1 hr at 4°.
After centrifugation as above, the supernatant solution (urea-soluble
fraction) was stored under N2 at 4". The urea-insoluble fraction was
resuspended in 10 ml of the same buffer and washed one additional time.
The amount of total protein in the soluble fractions was determined by the
method of Bradford (71), utilizing dye reagent supplied by Bio-Rad
Laboratories and lyopholized bovine serum albumin as a standadrd.
Urea-insoluble protein was measured after solubilization in SDS and
dialysis as described below.
Water-soluble and urea-soluble fractions were dialyzed overnight (MW
cutoff 3,500) at room temperature against a buffer containing O.IM
Tris-HCl, pH 6.8, 10 mM 2-mercaptoethanol and 0.1% SDS. The
urea-insoluble fraction was first dissolved in a minimum volume of 10 mM
Tris-HCl buffer (pH 6.8) containing 10 mM 2-mercaptoethanol, 1 mM EDTA,
and 4% SDS before dialysis
Immunoprecipitation of Cultured Rat Lens Proteins.

Dialyzed protein

fractions were obtained from lenses cultured in the presence of
[^Hjprenisolone and digested by incubating a 50 iil aliquot with 50 ul of 1
mg/ml proteinase K at 37** (described below).

The reaction was terminated
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after 1 hour by adding 100 yl of 0.1 M Tris-HCl buffer, pH 7.4 containing
7 M urea and 0.02% NaN3.

Two-hundred microliters of antiserum (1:3000,

described on p.68) was then added to each sample.

The blank samples

contained normal rabbit serum at the same dilution.
incubated at 4" for 10 hr.

Samples were

Bound material was separated by adding 0.8 ml

of a saturated ammonium sulphate solution and collecting the precipitate
by centriguation for 10 minutes in an Eppendorf microfuge (Model 5414).
Aliquots from the soluble fraction were removed and analyzed for
radioactivity by liquid scintillation counting.
Noncovalently bound material was removed from human lens protein
fractions by dialysis against a buffer containing SDS (described below),
or by extraction with ethyl ether (3X). The efficiency of extraction was
estimated by adding a standard amount of [3H]prednisolone (3,000 cpm) to
the protein fraction and counting the extractable tritium.

Recoveries of

greater than 95% of the added tritium were observed consistently.

A

portion of the lens protein fraction was subjected to radioimmunoassay
while another portion was assayed after digestion with proteinase K .
Identical values were obtained with the dialyzed and the ether-extracted
protein samples.
SDS-polyacrylamide

Gel

Electrophoresis.

Dialyzed

lens

protein

fractions were analyzed for radioactivity and total protein and then
diluted 1:1 in a sample buffer containing 0.1 M Tris-HCl buffer pH 6.8,
40% glycerol, 40 mM DTT, 2 mM EDTA, 1% SDS, and 0.02% bromophenol blue.
The mixtures were heated at 100* for 3 min.

Twenty-five ug of protein

containing approximately 5,000 cpm of tritium was loaded on polacrylamide
slab gels contaning

13% acrylamide

and

0.35% bisacrylamide

and

electrophoresed in the presence of 0.1% SDS utilyzing the buffer system
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described by Laemmli (72). The protein standard mixture (low molecular
weight) was obtained from Bio-Rad Laboratories.

Gels were stained for

protein with Coomassie Brilliant Blue R-250 and then fluorographed (73) in
order to localize tritium incorporation.

Exposures were performed at -80**

with Kodak X-OMAT AR5 X-ray film.
Induction of Cataracts in the Rabbit.

Rabbits were housed singly,

rested for one week after arrival, and fed water and standard rabbit chow
ad libitum.
procedure.

Steroids were administered intravitreously by the following
The pupils

of the eyes to be injected were first dilated with

1-2 drops of Mydriacyl (Alcon Laboratories). The rabbits were then
anesthetized by ether inhalation and 1 drop of local anesthetic (Alcaine,
Alcon Labs.) applied to the cornea.

The eye was gently proptosed with

blunt forceps and a 27 gauge needle inserted into the cornea in order to
drain the aqueous humor.

This needle was then removed and 0.2 ml of

steroid preparation (1 mM or 0.1 mM in sterile saline) injected into the
vitreous chamber by inserting a needle (27 gauge) through the posterior
aspect of the sclera.

For radioisotope studies, each eye received 0.2 ml

of a sterile solution containing 100 uCi of [^Hjcortisol, [3H]dexamethasone, or [3]prednisolone.

During this procedure, the penetrating needle

could be visualized through the lens and the dilated pupil.

Rabbits were

then returned to their cages and their eyes periodically examined with an
ophthalmoscope.
At intervals after injection, the animals were sacrificed by
injection with 2.5 ml of T-61 euthenasia solution (Hoechst).

Th eyes were

then excised and the posterior chamber exposed by perpendicular incisions
in the posterior sclera.

The vitreous was then carefully removed and lens

changes examined and photographed with a Zeiss binocular dissecting
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microscope.

Lenses were processed for electron microscopy or frozen at

-80° prior to protein fractionation.
Electron Microscopy.

Electron microscopy studies were performed on a

control lens and a representative cataractous lens removed 4 days after
the administration of prednisolone (200 nmoles).

Lenses were fixed at 4°

in triple aldehyde fixative (25% formalin, 1% acrolein, 1% glutaraldehyde,
O.IM cacodylate buffer pH 7.4, and 5 mM CaCl2).

Sections were stained

with saturated uranyl-acetate (50% ethanol) and lead citrate (74) and
analyzed with a JEOL lOOB electron microscope at an accelerating voltage
of 80 kV.

Results
The interaction of lenses with glucocorticoids was studied initially
in an in vitro system utilizing whole, explanted rat lenses cultured with
varying amounts of glucocorticoids.

In the presence of 5 to 50 nM

prednisolone, an opacification developed in the lenses in a time and
concentration dependent manner.

In contrast, no morphological changes

could be detected under similar incubation with 5 to 50 nM of pregnentetrol-one (4-pregnen-llB,17a,20a,21a-tetrol-one), a non-ketolic analog in
which the C-20 carbonyl is reduced to a hydroxyl group (Fig. 30)

Figure

22 shows the appearance of three representative lenses after 11 days of
culture.

Lens A shows no opacification and is typical of lenses Incubated

without prednisolone or with pregnen-tetrol-one.

Lenses B and C were

incubated with 5 and 50 nM prednisolone respectively, and show a centrally
located opacification which increases with prednisolone concentration.
This appearance differs from the posterior subcapsular changes which occur
in the human in vivo.

In an in vitro situation, the normal anatomic

Figure 22. Three representative rat lenses after elevi
days of culture. Lenses incubated with the non-ketolic
analog pregnen-tetrol-one had the appearance of lens A
The small light reflections visible in lens A are
artifacts of photography.

Effect of Prednisolone on Cultured Rat Lens

Onm

5nM

50nM
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orientation of the lens is lost and the development of opacification may
not exactly parallel the in vivo changes.
Single lenses which were incubated with 50 nM prednsiclone were
removed at intervals and the total proteins extracted into water-soluble,
urea-soluble, and urea-insoluble fractions.

As a function of time in

culture, there is a decrease in the amount of water-soluble proteins and a
commensurate increase in the amounts of urea-soluble and urea-insoluble
proteins (Fig. 23). Control lenses incubated without prednisolone did not
show any change.

This result is consistent with previous studies showing

that there is a decrease in water-soluble proteins with cataract formation
in vitro and in vivo (75, 70).
The possibility that glucocorticoids might form covalent adducts with
proteins in the intact rat lens was analyzed by culturing lenses in the
presence of 5 nM [3H]prednisolone.

These lenses were then fractionated

into water-soluble and urea-soluble fractions.

After dialysis against a

buffer containing 0.1% SDS, these fractions were analyzed for protein
content and incorporated radioactivity.
time dependent

Figure 24 shows that there is a

increase in protein associated prednisolone

water-soluble and urea-soluble lens fractions.

in the

By 11 days, the urea-

soluble proteins contain somewhat more incorporated tritium than the
proteins in the water-soluble fraction.

Figure 24 also shows that in each

fraction, virtually all the incorporated radioactivity is precipitable
with antiserum specific for proteins modified prednisolone (described on
p.68).

Therefore, the occurrence of tritiated proteins must be due to

covalent modification by [3H]prednisolone, and not to [3H]prednisolone
metabolism with subsequent incorporation of the tritiated intermediates
into newly synthesized macromolecules.
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Figure 23.

Single rat lenses incubated with 50 nM prednisolone

were removed at the indicated times and the total protein fractionated into water-soluble, urea-soluble, and urea-insoluble
protein. Lenses incubated without prednisolone did not show
any change.
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Figure 24. Lenses incubated with 5 nM [HJprednisolone
were removed at the indicated times and the total proteins
fractionated into water-soluble and urea-soluble protein.
Each point shows the mean + 1 S.E.M. for duplicate
determinations.
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The water-soluble, urea-soluble, and urea-insoluble extracts were
then electrophoresed under denaturing conditions in the presence of 0.1%
SDS.

Figure 25 shows the Coomassie blue staining pattern of each lens

protein fraction and the fluorographs of these fractions as a function of
time the lens was in culture.

Negligible changes were observed in

the

Coomassie blue staining of the water-soluble and the urea-soluble protein
fractions during incubation.

Protein bound [2H]prednisolone can be seen

to be present in both water-soluble and urea-soluble proteins.
labeled

urea-soluble

radioactivity

than

proteins
the

contain

labeled

a slightly

water-soluble

higher

proteins,

The

specific
and

the

incorporation of tritium into both protein fractions increases with
incubation time.
24,

These results confirm the observations shown in Fig.

In both the water-soluble

predominant

species

of

and the urea-soluble fractions, the two

[3H]prednisolone

labeled

approximate molecular weight of 18,000 and 22,000,

proteins

have an

By comparison with a

previous description of rat lens proteins (76), it would appear that the
18,000 MW protein can represent either a or Y crystallins and the 22,000
MW protein

is a subunit of 3 crystallins.

[3H]prednisolone incorporation
molecular weight protein.

A

small

amount

is also detectable in a much

of
higher

The identity of this protein is unknown.

Since the addition reaction between ketolic steroids and proteins is
slow, we reasoned that the introduction of a high, local concentration of
glucocorticoid might lead to sufficient protein modification so as to
produce experimental lesions in vivo.

This idea was tested by injecting

glucocorticoids directly into the vitreous chamber of rabbit eyes.

In

initial studies, young (4-6 week old) rabbits were administered 200 nmoles

Figure 25.

SDS polyacrylamide gel electrophoresis and

fluorography of lens protein fractions after incubation
of rat lenses with 5 nM [^Hlprednisolone. MW: molecular
weight, WS: water-soluble fraction, US: urea-soluble
fraction, UI: urea-insoluble fraction. CB: Coomassie
Blue staining of each lens protein fraction. 0, 7, 11 =
gel fluorographs after 0, 7, and 11 days of culture.
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Figure 26. Posterior views of two lenses photographed
through a binocular dissecting microscope. A: control
lens. B: lens removed eight days after the intravitreal
injection of 200 nmoles of prednisolone. The central
reflection in both lenses is an artifact of photography.

Figure 27 and 28.

Representative electron micrograph

sections of the posterior region of a lens removed
four days after injection with 200 nmoles of prednisolone.
Sections were stained with uranyl acetate and lead
citrate. LC: lens capsule, 1: area of fiber cell separation.

2: circular lesions within lens fiber cells.

Final magnification = 25,000x.

B
X

Figure 29. Enlarged views showing circular regions
of lower electron density within the lens fiber
cells. Final magnification: A = 33,333x; B = 41,666x.

•'S»"i^''i'ai. X.W«*./>'M.
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of prednisolone by injection into the vitreous chamber of one eye.
Contralateral eyes received an equivalent volume (0.2 ml) of saline.
Rabbits were examined daily by direct illumination with an ophthalmoscope
and all portions of the eye evaluated.

Lens changes in the prednisolone

treated eyes were first noted 48 to 72 hours after injection and appeared
as punctate, refractile deposits near the posterior pole.

Figure 26 shows

posterior views of two representative lenses removed eight days after
injection.

An opacification is apparent and consists of white, granular

lesions located immediately below the posterior capsule.
Figures 27-29 shows a series of electron micrographs obtained from
the posterior subcapsular region of a prednisolone treated lens 4 days
after injection.

Two classes of lesions are present in these sections.

The first is a disruption of the normal architecture in the subcapsular
lens fiber cells ("1", Figs. 27,28).

Fiber cells adjacent to the capsule

have separated along their membranes to produce large, vacuolated
regions.

Figure 27, in particular, displays an intermembranous region in

which this separation appears to be in the process of developing.

The

second type of damage ("2", Figs. 27, 28) consists of circular lesions
within the lens fiber cells.

These changes appear as areas of lower

electron density within the matrix of the crystallins.

Figures 29A and

29B show higher magnification views In which two of these lesions appear
to penetrate the fiber cell membranes.

Also present are associated

vacuoles, electron-dense granules, and a multi-vesiculated structure.
The origin of these intracellular changes is unclear, but they presumably
represent a disruption of normal lens crystallins.
Table 2 summarizes data for the induction of lens changes by 5
different steroids.

A total of 6 out of 6 prednisolone injected eyes
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showed posterior subcapsular opacifications.
outbred rabbits which were studied.

This number also includes 3

Opacification was induced only by

glucocorticoids having a reactive C-20,21 hydoxy1carbonyl function; e.g.
Cortisol, dexamethasone, and prednisolone (Fig. 30). Lens changes were
not produced by glucocorticoid analogs which either lack the C-21 hydroxyl
(17a-hydroxyprogesterone) or in which the C-20 carbonyl is reduced to a
hydroxyl (pregnen-tetrol-one).

Cortisol and dexamethasone also produced

opacities at a ten-fold lower dose (20 nmoles) in two rabbits which were
tested.
The occurence of glucocorticoid-lens protein adducts was examined in
three rabbits injected with 100 uCi of either Cortisol, dexamethasone, and
prednisolone.

After eight days, the lenses were removed, homogenized, and

extracted into water-soluble, urea-soluble, and urea-insoluble fractions.
After extensive dialysis against SDS to remove noncovalently
material, the amount of protein-bound tritium was measured.
shows the distribution of radioactivity
treated lenses.

bound

Figure 31

in these [3H]glucocorticoid

In the case of each steroid, the greatest proportion of

incorporated radioactivity appears in the urea-soluble protein fraction.
Injection with [3H]dexamethasone also results in the incorporation of
radioactivity in water-soluble as well as urea-soluble protein.
reason

for

this

difference

glucocorticoids is unclear.

between

dexamethasone

and

The

the other

Perhaps dexamethasone is unique in reacting

with water-soluble proteins to a significant degree.

Alternatively, if

the labeled urea-soluble protein is aggregated water-soluble crystallins,
these dexamethasone modified proteins may represent aggregates which have
not yet become insoluble.
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Steroid

Dose (nmoles)

Corti sol
Dexamethasone
Prednisolone
17a-0HPl
Pregnentetrol-one^

200
20
200
20
200
20
200
20
200

Eyes Injected

Posterior Subcapsular Changes

2
1
2
1
6
1
3
1
4

1l7a-hydroxyprogesterone.
24-pregnen-llB,17a,20a,21-tetrol-3-one.

Table 2. Summary of experimental rabbits injected with
different steroids.
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CH2OH
I
0 r-OH
=0

CORTISOL
CHoOH
I

I7a-HYDR0XYPR0GESTER0NE

c=o
HO. .^.JLc-OH

PREDNISOLONE

CHoOH
I
HCOH
HO. /s.,^-OH

PREGNEN-TETROL-ONE

DEXAMETHASONE

Figure 30. Structures of steroids assayed for cataractogenic
activity. Pregnen-tetrol-one is 4-pregnen-ilB,17a,20a,21tetrol-3-one.
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CORT

Figure 31.

DEX

PRED.

Distribution of protein-bound radioactivity

in lens protein fractions 8 days after the intravitreal
injection of 100 yCi of [ HJcortisol, [ H]dexamthasone,
3
or [ HJprednisolone. WS: water-soluble fraction, US:
urea-soluble fraction, UI: urea-insoluble fraction.
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C. Detection of prednisolone-lens protein adducts formed in vivo.

In order to detect the occurence of lens proteins modified by
prednisolone in vivo, a radioimmunoassay was developed for the measurement
of prednisolone-albumin

addition products.

Rabbit antisera was raised

against albumin which had been nonenzymatically modified with prednisolone
and used in a competition assay with [^HJprednisolone.

The following

section describes the details of this assay and the detection of
prednisolone adducts in human steroid-induced cataracts.

Methods
Antiserum

production

and

radioimmunoassay

procedure.

prednisolone-protein adducts were prepared as follows.

Synthetic

Fifty microliters

of a 12.6 mg/ml solution of prednisolone was added to a 0.45 ml solution
of HSA in 50 mM potassium phosphate buffer, pH 7.4, containing 10%
ethanol.

Ten microliters of a IM solution of NaCNBH3 was then added and

the solution incubated for 6 days at 37°.

In order to calculate the

degree of prednisolone incorporation, a second mixture was prepared which
contained, in addition, 4 x 10^ cpm of [^HJprednisolone.

Unbound material

was separated by extensive dialysis against a buffer of 50 mM potassium
phosphate pH 7.4 containing 10% ethanol, and gel filtration over a column
of Sephadex G-lOO, equilibrated with the same buffer.

A molar ratio of

prednisolone to HSA of 3.1:1 was obtained.
After lyophilization,

the pednisolone conjugated albumin was

dissolved in sterile saline and the concentration adjusted to 2 mg/ml. One
ml was emulsified with 1 ml of complete Freund's adjuvant

(Miles

Laboratories, Elkhart, IN) and injected into each of two New Zealand White
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rabbits.

Each rabbit received four intradermal injections over the back

(200 u9 each) and one injection in each hindquarter (100 ug). This
procedure was repeated at weekly intervals for 6 weeks.

The rabbits were

then rested for two weeks, following which a booster injection of 1 mg in
Freund's incomplete adjuvant was administered.
ml) on the tenth day after this injection.

The animals were bled (50

Sera were prepared, cleared of

debris by centrifugation at 500 x g and stored at -80°. Similar antibody
titres to prednisolone-albumin were observed in the two rabbits which were
immunized.

Radioimmunoassays were performed in 1.5 ml microfuge tubes

(Brinkman Instruments, NY) which contained the test antigen in 100 ul of a
buffer composed of 50 mM Tris-HCl (pH 8.0), 100 mM NaCl 0.1% gelatin and
0.02% NaN3.

Diluted antiserum (200 ul) which contained 5,000 cpm of of

[^HJprednisolone was then added, the samples incubated at 4** for 12-16 hr,
and antibody bound material separated from free material by precipitation
with 50% saturated ammonium sulphate.

The optimal dilution of antisera

which bound 50% of the 94 fmole of [^HJprednisolone present in the assay
was found to be 1:3,000.

The K^ for the binding of prednisolone was

calculated by Scatchard analysis to be 8.7 x 10^ M - ^
specificity

was

tested

prednisolone-protein
cross-reactivity.

by

assaying

various

adducts, and enzymatically

steroids,

Antiserum
synthetic

digested adducts for

The molar amount required to reduce the binding of

[^HJprednisolone by 50% compared to unlabeled prednisolone was calculated
from the standard curve.

Sensitivity was defined as the value of 2

standard deviations of the mean of duplicate blank values (77).
Enzymatic Hydrolysis.

Water-soluble proteins were digested by adding

5 mg of protein to an equal volume of digestion buffer (0.1 M Tris-HCl, pH
8.8 containing 1 mM EDTA and 1 mM DTT) and adding 1 mg/ml proteinase K
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(78).

The urea-soluble fraction was digested by first adding a two-fold

volume excess of 0.1 M Tris-HCl buffer, pH 8.8.

This dilution reduces the

urea concentration to a degree which does not inhibit protease activity.
The urea-insoluble fractions were solubilized by resuspending in 1 ml of
the digestion buffer containing proteinase K.
out at 37°.

All digestions were carried

The extent of digestion was estimated by the generation of

ninhydrin positive material (79). Proteolysis was judged to be complete
at 1 hr.

The reactions were terminated by adding 1 ml of 0.1 M Tris-HCl

containing 7 M urea.

Aliquots of digested samples were then subjected to

radioimmunoassay and immunoprecipitation as described above.
Human Lens Specimens.

Normal human lenses were obtained from the

Eye-Bank for Sight Restoration, Inc.

(New York, NY). The assayed samples

(n = 9) were from individuals aged 41 to 69 years.

The diabetic (n = 5 ) ,

traumatic (n = 1 ) , and senile (n = 11) cataractous lenses were from the
New York Hospital, Department of Surgical

Pathology.

cataracts were from patients of ages 59 to 62 years.

The diabetic
Three of these

lenses were from individuals with Type 1 diabetes mellitus who also
suffered from complications of retinopathy and nephropathy.

The senile

cataracts were obtained from patients of ages 59 to 87 years.

No

additional conditions known to contribute to cataract formation were
present in these cases.
The glucocorticoid-induced cataractous lenses (n = 7) were the
generous gifts of Drs. A.J. Bron, J.J. Harding, and V. Monnier.

Relevant

clinical information is summarized below.
Lens A: A 67 year old male patient with rheumatoid arthritis and
chronic bronchitis who received 5 - 7.5 mg of prednisolone per day for at
least 10 years.

In addition, this patient received 7.5 mg of cortisone

71.

per day for 1 year.

Other likely steroid-induced complications included

glaucoma and peptic ulcer.
Lens B: A 72 year old female patient with sarcoidosis who received an
ophthalmic preparation of 0.125
for about 8 years.

prednisolone phosphate two times per day

This patient also suffered from glaucoma.

Lens C: A 73 year old female with rheumatoid arthritis who received a
minimum of 5 mg of prednisolone per day for 5 years.

During this time the

patient also received alternate day therapy of 0.6 mg of betamethasone.
Lens D: A 61 year old male with bronchial asthma who received a
minimum of 10 mg of prednisolone per day for more than 10 years.
Lens E: A 74 year old male with bronchial asthma.

He received a

minimum of 5 mg of prednisolone for 5 years.
Lens F: A 56 year old female patient with rheumatoid arthritis and
anterior uveitis.
0.125

This person received an ophthalmic preparation of

prednisolone phosphate 4 times per day for 2 years.

In addition,

dexamethasone ointment was given 3 times per day for 2 years.
Lens G: A 75 year old female patient with bronchial asthma, glaucoma,
and diabetes mellitus (Type II).

This patient received 2.5 mg of

prednisolone for 5 years.
In all cases, nuclear sclerosis and posterior subcapsular changes
were evident by Ophthalmological examination.

Lenses A-C were lyophilized

and stored at 4°. Lenses D-G were received whole and stored at -20".

Results
The incubation of prednisolone with albumin in the presence of
NaCNBH3 produced an addition product which contained approximately 3 moles
of prednisolone per mole of albumin.

Polyclonal antisera was produced to
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this synthetic adduct and utilized in a competitive radioimmunoassay with
[^HJprednisolone.

Figure 32 shows a series of antigen inhibition curves.

The antisera was found to have a higher affinity for free prednisolone
than

for the immunogen:

prednisolone modified

albumin.

Enzymatic

digestion of prednisolone-albumin by protease K increased the reactivity
of the prednisolone protein adduct forty-fold, most likely by destroying a
large portion of the interfering tertiary structure of the protein.

A

similar increase in reactivity was observed after enzymatic digestion of
lens proteins modified by incubation with prednisolone in vitro.

The

minimum detectable amount of antigen at the 95% confidence limit was
calculated to be 0.10 pmoles for prednisolone and 0.33 pmoles for
predni solone-peptides.
Table 3 summarizes cross-reactivity studies with several steroids and
prednisolone-protein derivatives.
antisera

to

a

varying

degree,

Other glucocorticoids react with the
although

the

dexamethasone and betamethasone, react poorly

9-fluorocompounds,
(0.1% ).

A possible

complication in the use of the prednisolone-albumin immunogen is that
NaCNBH3 may reduce additional Schiff base adducts which form at the C-3
position of prednisolone.

This site would not normally be expected to

f o m stable adducts with proteins under aqueous conditions.

The antisera

however, appears to be primarily recognizing a D-ring conjugated hapten
since glucocorticoids with structural changes in ring D (i.e. prednisolone
hemisuccinate, 4-androsten-ll3 -ol-3,17-dione )
greater degree than

those with

large changes

cross-react to a much
in

ring A

(i.e.

tetrahydrocortisol).
This radioimmunoassay was then used to analyze enzymatic digests of
human lens proteins for the presence of prednisolone adducts.

Normal and
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100-

X3

-X Prednisolone (Pred)

I 50

•• Pred-albumin
"• Pred-lens protein
Pred-albumin (peptides)
Pred-lens protein (peptides

0.1

1.0

10

IOO

Prednisolone equiv. (^mole)

Figure 32. The relative percentage bound versus log dose curves
for anti-prednisolone-albumin antiserum with five antigens
3
utlilizing [ H]prednisolone as the competitor. Each point
represents the mean of duplicate determinations.
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COMPOUND

% CROSS REACTIVITY AT 50% BINDING

Prednisolone
Predni sol one-hemi sued nate
Corti sol
Prednisone
4-Androsten-ll 3-01-3,17-dione
Dexamethasone
Betamethasone
Tetrahydrocortisol

100
41
32
18
1.5
0.1
0.1
0.04

Predni solone-albumi n
Prednisolone-lens protein
Predni solone-albumi n (pepti des)
Prednisolone-lens protein (peptides)

1.0
0.7
40
41

Dehydroepiandrosterone
Etiocholanolone
17B-Estradiol

<0.001
<0.001
<0.001

Table 3. Percent cross-reaction relative to prednisolone
of anti-prednisolone-albumin antiserum with selected compounds.
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cataractous human lenses were homogenized and the proteins fractionated
into water-soluble, urea-soluble, and urea-insoluble portions.

Low

molecular weight material was removed by extraction with ethyl ether or
extensive dialysis against 0.1% SDS.

The water and urea-soluble lens

protein fractions were then analyzed by competitive radioimmunoassay with
[^HJprednisolone.
were analyzed

These fractions and the urea-insoluble fraction also

after digestion with proteinase K.

Antibody

binding

activity was found in the urea-soluble fraction of 5 out of the 7 steroidinduced cataracts assayed.

The binding activity in these lenses was found

to increase with enzymatic digestion in an identical manner as the lens
proteins modified with prednisolone in vitro.

None of the normal, other

catractous lenses, or other lens protein fractions displayed antibody
binding activity at an assay sensitivity of 0.33 pmole of prednisolone
equivalents.
Table 4 expresses this activity in terms of pednisolone equivalents
which were calculated from a standard curve of water-soluble lens proteins
which had been modified by prednisolone in vitro and digested with
proteinase K.

These values may not reflect prednisolone adducts alone

since several of the lenses were obtained from patients who were receiving
other steroids such as cortisone (lens A ) , betamethasone (lens C ) , and
dexamethasone (lens F ) . The degree to which these steroid-protein adducts
contribute to the antibody binding activity cannot be determined, but is
presumably low since these glucocorticoids were administered in much lower
amounts and, in the case of dexamethasone and betamethasone, the antiserum
reacts poorly with these steroids.
The cataractous lenses analyzed were from patients who had received
relatively low doses of corticosteroids (10 mg/day) for a varying number

76.

Lens Type
Normal:
Cataractous:

Traumatic
Diabetic
Senile
Steroid

N

Urea-Soluble Protein

9
1
5
11
7: A
B
C
D
E
F
G

N.D.
II

45.3*
67.3
5.3
7.3
6.2
N.D.
N.D.

*pmoles prednisolone equiv./mg protein.
N.D.: less than 0.33 pmoles prednisolone equiv.

Table 4. Glucocorticoid-lens protein adducts in
human lenses.
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of years.

The highest measured levels of prednisolone-protein adducts

were from two patienst (A and B) who had been treated with prednisolone
for more than eight years.

Of interest is that patient B had received

only an ophthalmic preparation of prednisolone, demonstrating that topical
as well as systemic routes of administration can lead to adduct formation
in vivo.

The two steroid-induced cataractous lenses (F and G) that did

not display antibody binding activity were obtained from patients who had
received the lowest cumulative dose of glucocorticoids of the lenses
assayed.

Presumably, these lenses had levels of steroid adducts which

were below the sensitivity of the radioimmunoassay.
The differences observed in the amount of steroid-protein adducts
present in the human cataractous lenses is most likely the result of
exposure to different cumulative doses of prednisolone.

Other factors may

play an important role in the onset of lens opacification. These include
inherent biochemical differences in the susceptibility of the lens to
protein modification.

The simultaneous accumulation of other covalent

additon products, perhaps as a result of nonenzymatic glycosylation or
carbamylation, may influence the course of lens opacification.

The report

of a more rapid onset of of unilateral cataract in the eye of diabetic
patients which had been treated with glucocorticoids points to the
possible additive effect of agents that can covalently modify proteins
(80).
Table 5 summarizes data for prednisolone-lens protein measurements in
the rat, the rabbit, and the human.
associated
adducts.

with

approximately

Of note is that these cataracts are

equivalent

amounts

of

prednisolone

It would appear that when the lens has accumulated this much

modification, a visible opacification occurs.

In all three examples.
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Protein Fraction
Water-Soluble

Urea-Soluble

Urea--Insoluble

Rat

1-10*

1-10

N.D.

Rabbit

N.D.

5.3

N.D.

Human

N.D.

5.3-67.3

N.D.

*pmoles prednisolone equiv./mg protein
N.D.: less than 0.33 pmoles prednisolone equiv.

Table 5. Summary of prednisolone-lens protein adducts
measured by radioimmunoassay.
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prednisolone addition products were detected in urea-soluble protein.

The

rat cataract, which differs in being nuclear in localization, also shows
glucocorticoid adducts in water-soluble protein.
There are two possible explanations for why prednisolone tends to be
associated with urea-soluble protein.

One is that prednisolone may

concentrate in the hydrophobic environment of the membrane and react
preferentially with proximal membrane proteins.

The second possibility is

that soluble crystallins, once modified by prednisolone, may undergo
structural alterations which lead to precipitation and association with
membranes.

This second possibility is consistent with the decrease in

water-soluble protein which is seen with the in vitro rat cataract (Fig.
23) and with the membrane associated changes observed in the electron
micrographs of rabbit cataracts (Figs. 27-29).
The unusual finding from these studies is that visible opacifications
appear to be associated with yery low levels of protein modification.

One

mechanism for the role of protein modification in the steroid-induced
catacract is that prednisolone may attach to the lens crystallins and
induce sufficient conformational

changes so as to lead to disulfide

cross-linking and the formation of high molecular weight aggregates.
Evidence for this mechanism has been presented for both the hyperglycemic
and the cyanate induced cataract (16, 60). Alternatively, because the
level of modification is so low, it is possible that the modification and
inactivation of an enzyme or membrane ionophore is the event which
initiates lens opacification.

ATP metabolism in the lens for example, has

been shown to be affected by the administration of Cortisol in vitro (81,
82).
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D.

Studies of the effect of prednisolone modification on lens crystallins
in vitro.

In order to gain insight into the role of glucocorticoid modification
in cataractogenesis, the effect of incubating pednisolone with lens
proteins in vitro was studied.

The following studies demonstrate that the

modification of lens crystallins by prednisolone imparts on the proteins
an increased susceptibility to sulphydryl

oxidation, leading to the

development of high-molecular weight aggregates which scatter light.

Methods
Preparation of Lens Protein.

Normal human lenses were decapsulated

and homogenized on ice in a glass tissue homogenizer containing nitrogen
saturated phosphate buffered saline (PBS, 1.5 ml per lens).

The mixture

was centrifuged at 20,000xg for 30 min. at 40, and the supernatant
solution (water-soluble fraction) recovered.

After dialysis (MW cutoff

3500) against PBS, the protein solution was filtered through a sterile
Millipore membrane (0.45 \im cutoff).
Acetylated lens protein was prepared by incubating a solution of lens
protein (10 mg/ml) with 15 mM acetylsalicylic acid for 18 hr at 37°.
Unreacted acetylsalicylic acid was removed by dialysis against PBS.

The

degree of acetylation was estimated by a parallel incubation which
contained,

["I^Cjacetylsalicylic

acid

(26.2 mCi/mnol, Amersham).

A

specific activity of 10 mole/mg lens protein was obtained.
Urea-soluble protein was obtained from a human steroid-induced
cataract as described on p. 54.
Table 4.

This lens corresponds to lens "A" in
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Lens Protein Incubations.

A 20 mM solution of prednisolone was

prepared in methanol and 10 ul added to 1 ml of sterile lens protein
solution (10 mg/ml).

The final concentration of prednisolone was 200

M

and methanol was 1%.

Control incubations contained 1% methanol as well.

Radioactive incubations contained 200 uM prednisolone supplemented with 2
uCi/ml of [2,4,5,7-3H]prednisolone (61 Ci/irinol).

All incubations were in

sealed tubes, under nitrogen, in the dark, and at 37°.

Alternatively,

some incubations were performed in sterilized, polystyrene cuvettes
(Fisher Scientific, Pittsburgh, PA). The development of opalescence in
the incubated solutions was measured by the optical density at 550 nm
(16).

At

intervals,

[^HJprednisolone

sterile

incorporation

aliquots
measured

were
by

removed

and

precipitation

the
with

10

trichloroacetic acid (83).
Gel

Filtration

Chromatography.

The formation of high-molecular

weight aggregates in the lens protein incubations was analyzed by
chromatography over a column (1.5 cm x 48 cm) of Biogel A-5m (BioRad
Laboratories) equilibrated with 50 mM potassium phosphate buffer (pH 7.4)
containing 0.02% NaN3.

The column was calibrated with the following

molecular weight standards: blue dextran, thyroglobulin (bovine), gamma
globulin (bovine), ovalbumin (chicken), myoglobin (equine), vitamin B-|2»
and

[^HJprednisolone.

Samples

(5 mg) were chromatographed

temperature at a flow rate of 3.4 ml/hr.

at room

Lens proteins incubated with

[^HJprednisolone were dialyzed against PBS prior to chromatography.
Fractions (0.85 ml) were collected and analyzed for protein by the method
of Bradford (71).

Aliquots (100 ul) also were counted by liquid

scintillation in order to detect tritium incorporation.
Lens proteins were reduced by treatment with 50 mM dithiothreitol
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(DTT, Sigma) for 1 hr.

For gel filtration analysis of these samples, the

resin was equilibrated with a buffer containing 50 mM potassium phosphate
(pH 7.4), 0.02% NaN3, and 30 mM DTT.
Urea-soluble protein was analyzed by the same chromatographic system
with the exception that the column buffer contained in addition, 10%
ethanol.

The presence of prednisolone-protein adducts was analyzed by

radioimmunoassay after enzymatic hydrolysis with proteinase K as described
on p. 68. Five adjacent fractions were pooled for these determinations.
Peptide Mapping.

Tryptic peptides were prepared from high-molecular

weight comnplexes isolated by gel-filtration chromatography of lens
proteins incubated with [^HJprednisolone.

Fractions 29-32 were pooled,

yielding 0.51 mg of protein with a specific activity of 2.8x10^ cpm/mg.
The proteins were then reduced, aminoethylated, hydrolyzed with trypsin,
and analyzed by reverse-phase HPLC as described on p. 17.

Results
The incubation of prednisolone with human water-soluble lens proteins
leads to the gradual development of opalescence of the solutions.

In

initial experiments, the rate of opalescence was found to vary with both
prednisolone and lens protein concentration.

Figure 33 shows two

representative solutions photographed after 50 days of incubation.

Lens

protein incubated with 200 \M prednisolone (right) display marked light
scattering, while a control solution containing lens protein alone (left)
shows only a modest opalescence.
Figure 34 shows the time-course for this phenomenon, measured by the
absorbance at 550 nm..

Incubation with prednisolone (200 uM) leads to a

gradual increase in optical density which becomes significantly more rapid

Figure 33.

The appearance of two lens protein

solutions after 50 days of incubation at 37 .
The solution on the right contained 200 yM
prednisolone.
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after 30 days.

A control solution shows only a moderate, linear increase

in optical density.
[^HJprednisolone

A prednisolone incubation supplemented with 2 uCi of

demonstrates that covalent prednisolone-lens

protein

adducts form at a linear rate (Fig. 34B). Presumably, after 30 days of
prednisolone incorporation, aggregates which are large enough to scatter
light begin to form and result in a more rapid increase in optical
density.
The interpretation that the nonenzymatic addition of prednisolone to
lens proteins is involved in the development of light scattering was
confirmed

by pretreating

proteins with acetylsalyci lie acid.

This

reagent, under mild conditions, acetylates the free amino groups of
proteins, particularly the e-amino groups of lysine residues.
Fig. 34,

As shown in

lens proteins in which the primary amino groups have been

chemically blocked fail to incorporate prednisolone and do not become
opalescent.
Calculations from the prednisolone incorporation curve show that at
35 days, 650 pmoles of prednisolone is incorporated per mg of lens protein.
Assuming a crystallins subunit molecular weight of 20,000 daltons, this
calculates to be an average molar modification of 1 prednisolone molecule
per 77 crystallins subunits.

Although this is 10 to 50 times the amount

observed in either the experimental or the human steroid cataract, the
level of modification is still extremely low.

This would suggest that the

conformation of lens proteins must be extremely sensitive to the presence
of the prednisolone ligand.
Several studies have emphasized the role of sulphydryl oxidation in
the aggregation of lens proteins in vitro and in vivo (16, 70, 84-87).

We

examined the effect of adding the reducing agents dithiotreitol (DTT) or

to

20

30

40

50

60

Incubation time (days)

Figure 34. The time course for the development of opalescence (A)
and prednisolone incorporation (B). (t): lens proteins incubated
with prednisolone,
prednisolone,

(o): acetylated lens proteins incubated with

(^): control lens proteins incubated alone.
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glutathione (GSH) on the light scattering elements present in the lens
protein incubations.

As shown in Figure 35, the addition of DTT was found

to rapidly reverse much of the opalescence which had developed during
incubation.

Glutathione had only a minimal effect.

This is probably due

to the inability of the glutathione tripeptide to penetrated extensively
aggregated proteins and reduce the disulfide crosslinks.

A similar

discrepancy in the reducing action of GSH and DTT has been observed for
glucose induced lens protein aggregation in vitro and in vivo (16, 87).
The lens protein aggregates were further investigated by gel
filtration chromatography on Bio-gel A-5.

Figure 36 shows the elution

profile of water-soluble lens proteins after 1 and 50 days of incubation.
The day 1 pattern shows 5 major protein peaks, which correspond to the
major crystallins proteins present in the human lens (Y, B ] , 3h> ^> "HMW»
(8S)).

It is apparent that after 50 days of incubation, there is an

increase in the amount of high molecular weight proteins present.

In

comparison to the control incubation, the prednisolone incubated solution
shows a greater than two-fold increase in the amount of high-molecular
weight proteins present.

The aggregates elute in the column void volume,

indicating that they are composed of molecules having a globular molecular
weight of at least 5 x 10^ daltons.

These aggregates are near if not

already at the size estimated by Benedek to be sufficient to scatter light
in the lens (50 x 10^ daltons, (89)).
Figure 36 also shows that there is a significant decrease in the
amount of g^ ^^^ 3l crytsallins present in the prednisolone incubation.
Therefore, the high-molecular weight species appear to be complexes of
6h. 31» and presumably some a crystallins.
Figure 37 shows the gel filtation pattern of lens protein incubations
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Figure 35. The effect of the reducing agents GSH and DTT
on the prednisolone-induced opalescence. The final
concentration of each reducing agent was 1 mM.
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Figure 36. Gel filtration chromatography of water-soluble lens proteins. Top: after 1 day of incubation. Bottom: after 50 days. The
numbers denote M^ standards, V = void volume, P = prednisolone.
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which had been supplemented with [^HJprednisolone.

The majority (55%) of

the incorporated radioactivity Is associated with the rapidly eluting
high-molecular weight complexes.

The addition of DTT (Fig. 37, bottom)

decreases the amount of high molecular weight protein present by about 50
With DTT treatment, there is an increase in the amount of protein eluting
in the region of a, 6^* and B] crystallins and there is a corresponding
redistribution of protein incorporated [^HJprednisolone.
Figure 38 shows the reverse-phase HPLC elution of tryptic peptides
prepared from the high-molecular weight aggregates isolated by Biogel-A5
chromatography.

The majority of the incorporated prednisolone is present

in 4-6 peptides, with small amounts present in other peptide peaks.

It

would appear that although the high-molecular weight complexes are
composed of several crystallins types, there is only a small number of
lysines within these proteins which can react with prednisolone.
Having determined

that the majority of prednisolone which is

incorporated in vitro is present in high-molecular weight complexes, we
decided to analyze protein from a human steroid-induced cataract which
previously was shown to contain prednisolone-protein adducts.

Figure 39

shows the gel-filtration profile of urea-soluble protein derived from lens
A (Table 3) chromatographed on Biogel A-5 in the presence of 10% ethanol.
Fractions were

pooled

radioimmunoassay.

and

analyzed

for prednisolone

adducts by

Almost all of the protein bound prednisolone is

associated with in high-molecular weight proteins which elute early in the
chromatogram.

Preincubation

of these proteins with

dithiothreitol

decreases the amount of this high molecular weight material and increases
the amount of protein present in the a and 6 regions of the chromatogram.
In addition, about half of the prednisolone protein adducts redistribute
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Figure 37. Gel filtration of lens proteins incubated with [ H]prednisolone. Top: lens proteins at Day 50; the horizontal bar shows fractions
pooled for peptide mapping. Bottom: Day 50 proteins reduced with DTT.
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Figure 38. Reverse-phase HPLC tryptic map of the high-molecular
weight complexes isolated from lens proteins incubated with
3
[ HJprednisolone.
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40

50
60
Fraction

Figure 39. Gel filtration analysis of the urea-soluble protein obtained
froma human steroid-induced cataract.

Bottom:

after reduction with DTT.
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to these lower molecular weight regions.
vivo,

prednisolone

modified

lens

These results indicate that j_n

proteins

are

also present

disulphide-linked complexes which are reducible with DTT.

as
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E.

Conclusion.

The experiments which have been described provide a biochemical basis
for how glucocorticoids can react with lens crystallins to cause cataract
formation (Figure 40).

Prednisolone enters the lens fiber cells and

reacts with the amino groups of the lens crystallins.

This presumably

induces a conformational change and the unmasking of protein sulphydryl
groups.

Disulphide bond exchange then occurs and protein aggregates form,

leading eventually to complexes which refract light.

These aggregates

would readily become membrane associated and soluble only in urea.
In the native state, the crystallins proteins exist as hydrophobically associated polymers of molecular weights between 200,000 and 1,000,000
daltons (88). Disulphide exchange therefore, would only need to involve
about 50 molecules in order to generate aggregates of the size estimated
by Benedik (50 x 10^ daltons) to be sufficient to scatter light (89).
The acetylation experiments indicate that lens proteins can be
protected

in vitro

modification.

from

the

damaging

effects of glucocorticoid

It is surprizing that acetylation of lens proteins does not

induce aggregation, even when the proteins are modified to a 1000 fold
higher specific activity than they are with prednisolone.

Evidently, the

presence of acetyl moieties does not alter significantly the conformation
of lens crystallins.

Prednisolone may also be attaching to specific sites

in the crystallins proteins where its presence readily disrupts protein
conformation and induces disulphide exchange.
The lens may serve as a useful model for the biochemical effects
of glucocorticoid modification.

It would be interesting to investigate

other toxic manifestations of glucocorticoids and examine whether the
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Figure 40. Proposed mechanism for the steroid-cataract.
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modification of critical proteins is also involved.

In addition, the

protective effect of acetylation suggests a novel therapeutic use of
aspirin, or other acetylating agents in protecting biologically critical
proteins from the damaging effects of protein modification.
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4.

Nonenzymatic Modification of Proteins by 16a-Hydroxyestrone
in Systemic Lupus Erythematosus.

97.

A.

Introduction.

Systemic Lupus Erythematosus or SLE, is considered to be the
prototype of a multisystem, autoimmune disease (90). Although SLE is
often thought to be a rare disease, recent statistics have shown it to
be as prevalent as 1 in 8000.
disease

are diverse, and

The clinical manifestations of this

include fever, an erythematous

rash,

polyarthralgia and arthritis, polyserositis, anemia, thrombocytopenia,
and renal, neurologic, and cardiac abnormalities (Table 6 ).

In most

cases, these symptoms pursue an irregular, but relentless course in
which episodes of active disease are interspersed with periods of
complete or near-complete

remission.

The patients who eventually

succumb usually do so because of vascular lesions affecting the kidneys,
central nervous system, or other vital organs; many die of the
complications of secondary infections (92).
Although the etiology of SLE is not known, much of the pathology
can be attributed to immune complex deposition resulting from the
production of autoantibodies, or antibodies to self-antigens.

Anti-

bodies have been identified against an array of nuclear and cytoplasmic
components which are neither organ, nor species specific.

In particu-

lar, the presence of high titres of anti-DNA antibodies can be diagnostic of SLE.

Other immunological abmormalities have been found to

occur in SLE, including defects in T-cell function, and deficiencies in
certain components of the complement system.
An unusual feature of SLE is its strong predilection for women.
Several observations have implicated the role of female hormones in
either the onset or the severity of the disease (93). For example, SLE
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Clinicat manlfMtationt during tht c o u r M of sy«t»mic lupus
•fythtmaloMJS
Manifestation

Cumulative percentage of patients

Arlhntis and arthralgias
Fever
Skin eruptions
Lymphadcnopathy
Renal involvement
Anorexia, nausea, vomiting
Myalgia
Pleuntis
Central nervous system abnormalities

92
84
72
59
53
53
48
45

26

SOUliCE After Dubois

Lftboratory abnonnalities in tystamic lupua arythamatoaus
Abnormality Percent of patients
HEMATOLOGIC

Anemia (Hb < 11 g/100 ml)
Leukopenia ( W B C < 4500/mm')
TTirombocytopenia (platelets < 100.000'
mm')
Positive direct Coombs test
Circulating anticoagulants

72
61
15
14
Rare

IMMt7»OLOGIC

Positive tests for A N A
Positive L E cell tests
Hypocomplcmentemia
Increased > globulin ( > 1.5 g/l(X) ml)
Positive tests for rheumatoid factors
Biologic false positive tests for syphilis

99
60-80
75
60-77
20
15

Table 6. Clinical and laboratory abnormalities
present in SLE (91).
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is most common during the reproductive years and the vast majority of
patients who present with the disease during this time are female
(almust 13:1, female:male).

There is in addition, a high incidence of

SLE among males with Kl inefelter's syndrome (the XXY genotype).

A

number of reports have described the adverse effects of estrogens on the
course of the disease.

Among these are birth control agents (94,95),

the menstrual period (96), and the possible adverse effect of pregnancy
both during (97) and after parturition (98).
A number of investigations have examined the pattern of sex steroid
metabolism in patients with SLE. Although both male and female patients
with SLE had normal levels of estrogen (99), Lahita and co-workers
analyzed in more detail, estrogen metabolism in these patients.
41 shows the pathway of estrogen metabolism in the human.
studies, the injection of 6,7-[3H]estradiol

Figure

In initial

was found to lead to

increased amounts of urinary 16a-hydroxyestrone; in preference to
metabolites of 2-hydroxylation (35). Subsequent work showed an overall
increase in the rate of 16-hydroxyl ation in both male and female
patients with SLE (34); and with the development of a specific
radioimmunoassay, an increase in the plasma level of the metabolite
16a-hydroxyestrone (100, 101).
Having determined that 16a-hydroxyestrone
non-enzymatically

with

protein

amino

(16aOHE) can react

groups, we considered

two

mechanisms by which this protein modification activity might contribute
to either the etiology or the pathology of SLE.

Pregnancy and phasic

estrogen secretion during the menstrual cycle increases the level of
16-hydroxyl ated metabolites and may exacerbate the disease by increasing
the formation of these adducts.

If these adducts are antigenic in
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susceptible individuals, they might initiate or contribute to the immune
complex manifestations of the disease in much the same way that
penicillin-protein
individuals (102).

adducts produce penicillin allergy in sensitive
Alternatively, 16a0HE might covalently modify key

proteins involved in immune regulation.

The modification of lymphocyte

surface proteins could disrupt cellular interactions and initiate the
immune dysfunction which is characteristic of SLE.
The following chapter describes the nonenzymatic reaction of 16aOHE
with a number of proteins, the detection of these adducts in vivo, and
studies of the occurence of anti-estrogen antibodies.
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B.

The reaction between 16a-hydroxyestrone and proteins in vivo.

As a first step toward analyzing the occurence of 16aOHE-protein
adducts in vivo, 16a-[3H]hydroxyestrone was incubated with whole blood
in vitro and the distribution of covalent 16aOHE-protein adducts
determined.

Membrane proteins were found to be labeled to the highest

specific activity and the interaction of 16aOHE and membrane proteins
was studied using the erythrocyte as a model cell system.

A method for

the purification and detection of these adducts was developed and used
to quantitate the formation of these adducts in vivo.

Methods
[^H3l6aOHE-whole blood incubations.

For whole blood incubations, 2

iiCi of [3H]16aOHE was added to a 1.5 ml microfuge tube (Brinkmann) and
the solvent evaporated under a flow of nitrogen.
with 50 ul ethanol and evaporated again.

The residue was washed

Whole blood from a normal

volunteer was anticoagulated with EDTA and 0.6 ml added to the tube.
Six microliters of a 1% solution of sodium merthiolate was included as a
bacteriocidal agent.

The mixture was incubated at 37<^ with gentle

shaking and 0.1 ml aliquots removed at intervals.

Cells were separated

from plasma by centrifugation for 30 sec in an Eppendorf microfuge
(model 5415).

The plasma was dialyzed against 50 mM potassium phosphate

buffer pH 7.4/10% ethanol and then chromatographed on G-lOO column as
described on p. 15.

Cells were washed three times with 50 ml phosphate

buffered saline and the cell pellet lysed by the addition of 0.15 ml
distilled H2O. The lysate was dried under a heat lamp and oxidized in a
Packard Tri-Carb sample oxidizer.

Radioactivity was determined by
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scintillation counting and recovery from the oxidation corrected with a
tritium recovery curve.

Background radioactivity was determined from

the zero time point and subtracted for both plasma and cells.
For electrophoresis, 0.2 ml of a washed red cell suspension (45%
v/v) in PBS with 0.5 mM EDTA was added to a microfuge tube containing 10
IiCi [3H]16aOHE.

In order to determine total Schiff base formation, a

second mixture contained in addition, 2.4 ^mol of NaCNBHs.

At the end

of a 24 hr incubation, the tubes were centrifuged, the supernatant
removed, and the cells lysed by the addition of 12 ml of ice-cold 5 mM
sodium phosphate buffer, pH 7.4 containing 1 mM phenyl methylsulfonyl
fluoride and 0.5 mM EDTA.

Red cell membranes were prepared following

the method of Dodge et al. (103).

Lysates were centrifuged at 29000 x g

for 30 min at 4° and the supernatant reserved for assessing [3H]16aOHE
adduct formation with cytosolic protein.

The membrane pellet was washed

in buffer containing 10 mM sodium phosphate, pH 7.4 and 0.5 mM EDTA and
centrifuged at 29000 x g for 30 min.
repeated three more times.

This washing procedure was

The final membrane pellet was then dissolved

by the addition of 50 ul of 10 mM Tris-HCl buffer, pH 6.8 containing 4
SDS and 10 wM 2-mercaptoethanol.

The solubilized membranes were

dialyzed overnight against a buffer containing 10 mM Tris/HCl, pH 6.8,
10 mM 2-mercaptoethanol and 0.1% SDS.

The membrane preparation was then

subjected to electrophoresis or acid precipitation.
Polyacrylamide gel electrophoresis was performed on a 7 % slab gel
according to the method of Laemmli (72).

Hemoglobin and a protein

standard mixture were run in adjacent lanes.

Gels were stained with

Coomassie Blue and then fluorographed by the method of Laskey and Mills
(73).
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Acid precipitation of red cell lysates, membranes and cytosol was
modified from the method of Kennel

(83).

Briefly, protein was

precipitated with a final trichloroacetic acid concentration of 5% and
incubated at 0° for 30 min.

The precipitate was collected onto

Millipore filters (0.45 urn), washed successively with 10% trichloroacetic acid, and 70% ethanol, dried, and then measured for radioactivity.
Synthesis of 16a-hydroxyestrone conjugates for antibody production.
Fifty microlitres of a 10 mg/ml solution of 16aOHE in ethanol was added
to 0.45 ml of a 20 mg/ml solution of HSA in 50 mM potassium phosphate
buffer, pH 7.4.

A second mixture was prepared which contained, in

addition, 400,000 cpm of [3H]16aOHE.

Ten microlitres of a 1 M solution

of sodium cyanoborohydride (NaCNBH3) was then added and the solutions
incubated for 6 days at 37".

For the synthesis of the 16aOHE-albumin

Heyns rearrangement product, the NaCNBHs was omitted.
At the end of the incubation, the solutions were dialyzed overnight
against 1 litre of 50 mM potassium phosphate buffer, pH 7.4 containing
10% ethanol (v/v).

The dialyzed material was then subjected to gel

filtration over a column of Sephadex G-lOO (1 x 29 cm), equilibrated
with the same buffer.

The flow rate was 3 ml/hr.

The protein eluate

was pooled and the total protein determined by the method of Bradford
(71) utilizing bovine serum albumin as a standard and dye reagent
supplied by Biorad Laboratories.

The molar ratio of 16aOHE to HSA was

calculated from the second incubation by measuring the quantity of
[3H]16aOHE covalently bound to HSA.
16a-hydroxyestrone-lysine (16aOHE-lysine) was prepared as described
on p. 35.

16aOHE-albumin peptides were generated by Incubating 60 nl of

NaCNBH3 reduced 16aOHE-albumin (1.2 mg/ml in 0.3 M potassium phosphate
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buffer, pH 9.0) with 10 U of trypsin immobilized on agarose (Sigma) at
37° for 12 hr.

Complete enzymatic hydrolysis was assessed by HPLC gel

filtration utilizing an 1-125 column (Waters Associates, Milford, MA)
and monitoring at 280 nm.
Rabbit immunization.

After lyophilization, the cyanoborohydride

reduced 16aOHE-HSA product was dissolved in sterile saline and the
concentration adjusted to 2 mg/ml.
complete Freund's adjuvant
rabbits.

One ml was emulsified with 1 ml

and injected into 2 New Zealand White

The immunization protocol, and antisera assay procedure

followed the methods described on pp. 68-69.
Erythrocyte membrane preparation.

Whole blood was obtained by

venipuncture and was anticoagulated with EDTA.

For the preparation of

red cell membranes, 6-7 ml of blood was centrifuged for 10 min at 500 g
and the plasma removed and stored at -80" for the later determination of
free 16aOHE.

The buffy coat was discarded and the remaining red cells

were washed three times with a ten-fold excess of phosphate buffered
saline (PBS).

For each 16aOHE-lysine determination, 2 ml of packed red

cells were lysed by the addition of 12 ml of 5 mM sodium phosphate
buffer pH 7.4, which contained 1 mM phenyl methylsulfonylflouride and 0.5
mM EDTA.

This mixture was frozen and thawed once, and membrane proteins

prepared using procedures described previously (103).
16aQHE-lysine purification.

A flow chart for the purification and

quantitation of 16aOHE-lysine is shown in Fig. 47.

Crude membranes were

isolated from cell lysates by centrifugation at 29,000 g for 30 min.
After repeated washings, the pellet was suspended in 2 ml of 50 mM
sodium phosphate buffer, pH 7.4.

A 4 M solution of NaBH3 was prepared

in 1 mM NaOH and 250 ul introduced into each pellet suspension.

The

106.

mixture was incubated for 10 min at room temperature followed by 50 min
on ice.

The reaction was quenched and the lipid soluble material

removed by sequential extraction with 18 ml of acetone:ethanol

(1:1,

v/v), followed by 10 ml of acetone:ethanol and 2 ml of ethyl ether.

The

insoluble material was then collected by centrifugation (lOOOg x 20 min)
and hydyrolyzed with 5 ml of 6 N HCl (110° for 8 hr) in order to generate free 16aOHE-lysine.

The hydrolysate was evaporated in a Speed-

Vac concentration apaparatus (Savant Instruments).

The pellet was redis-

solved in 0.5 ml distilled water, and the solution evaporated again.
Phenyl-Sepharose, SM-2, and HPLC Chromatography.

The hydrolysate

was dissolved in 2 ml of a buffer containing 5 mM sodium phosphate, pH
7.4 and 4 M NaCl.

The pH was adjusted by the addition of 35 ul of 10 M

NaOH and the solution extracted with 2 ml of ethyl ether.

The layers

were mixed on a rocking platform for 10 min and the ether layer cleared
by centrifugation

for 3 min at 500g.

The ether was removed by

aspiration and the extraction repeated two more times.

The aqueous

layer was then heated to 45^ for 30 min to remove residual ether.

The

solution was layered onto a 1.1 x 2 cm column of phenyl-Sepharose
(Pharmacia) equilibrated with a buffer containing 4 M NaCl and 5 mM
sodium phosphate, pH 7.4 and flowing at a rate of 6 ml/hr.

Elution was

monitored at 280 nm with a Uvicord II (LKB Instruments).

Unmodified

amino acids, which were detected with a Beckman 119C amino acid analyzer
(104), were found to elute in the first 10 ml of the starting buffer.
The fraction containing 16aOHE-lysine was eluted with 8 ml of 1 mM NaP04
buffer, pH 7.4.

Subsequent elution with methanol/water

(1:1, v/v)

removed additional UV absorbing material and radioactivity from the
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column.

This latter material did not co-elute with [3H]16aOHE-lysine

when analyzed with HPLC.
The 1 mM sodium phosphate buffer wash was evaporated in a Speed-Vac
apparatus and the volume adjusted to 2 ml with distilled water.

This

material was applied to a column (0.8 x 4 cm) of SM-2 resin (Bio-Rad
Laboratories) equilibrated with 1 mM sodium phosphate buffer, pH 7.4.
The resin was washed previously with water, methanol, water, and 1 mM
sodium phosphate buffer, pH 7.4.

The column was eluted with 6 ml of 1

mM sodium phosphate buffer, pH 7.4 at a flow rate of 6 ml/hr. The
eluting solvent was then changed to methanol/water (1:1, v/v). This
latter fraction contained 16aOHE-lysine.
A portion (50-200 u"l) of the SM-2 eluate was Injected into a
Hewlett-Packard 1084B liquid chromatograph which contained an RP-8
(Hewlett-Packard) reverse-phase column and a uBondapak C]8 (Waters
Associates) guard column.

The mobile phase consisted of a gradient of

10 mM sodium phosphate, pH 7.0/50% methanol which increased linearly to
100% methanol from 0 to 20 min.

The flow rate was 1 ml/min and solvent

and column temperature was maintained at 40°. For each analysis, twenty
1 ml fractions were collected in 1.5 ml microfuge tubes (Sarstedt).

The

fractions were then evaporated in a Speed-vac and subjected to radioimmunoassay as described below.

The entire HPLC elution therefore, was

analyzed for each protein hydrolysate.
For the detection of radioactive flow, the column eluate was mixed
with scintillation fluor (Flo-Scint II, Radiomatic Instruments) which
flowed at a rate of 3 ml/min and analyzed with a Flo-One detector (Radiomatic Instruments, Inc.)

Alternatively, 1 ml fractions were collected

and counted in a scintillation spectrometer after the addition of 6 ml
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of Hydrofluor (National Diagnostics).
Lymphocyte preparation.

Forty ml of whole blood was withdrawn from

each individual and anticoagulated with EDTA.

The blood was then

diluted 1:1 with PBS and divided into two portions.

Each portion was

centrifuged through a 15 ml layer of the density medium Ficoll-Pacque
(Pharmacia) following the procedures recommended by the manufacturer.
The lymphocyte layer was withdrawn by aspiration and washed three times
with PBS.

The cell pellet was then lysed and membranes prepared using

the same procedure described for red cells.
16aOHE-lysine was purified from lymphocyte membranes using the
method described above with the modifications that reduction was with
0.5 mmole of NaBH4 and acid hydrolysis was with 2.5 ml of 6 N HCl.
Basement membrane preparation.

Kidney tissue was obtained at

autopsy from two women with SLE and two women without a history of
autoimmune or kidney disease.

Each specimen consisted of a coronal

section of one-half of one kidney.

Glomerular basement membrane was

prepared according to the original

procedure of Spiro (105) and

employing the modifications of Beisswenger et al. (106) for human
specimens.
thaw.

Each half-kidney was placed on ice and allowed to partially

The kidney was divided into thin sections and the cortex sliced

away from the medulla, which was discarded. Cortical slices were further
sectioned into 1-2 mm pieces and forced through a 150 mesh sieve with
the bottom of a small beaker.

The disrupted tissue was collected in a

receiving pan containing ice-cold saline (0.85

NaCl).

Once the entire

sample was processed, the suspended material was poured through an 80
mesh sieve which served to retain the tubular material but allowed the
intact glomeruli to pass through and be collected on a 170 mesh sieve.
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After a saline wash, the glomeruli were collected in a 50 ml conical
centrifuge tube.

Examination by phase contrast microscopy showed that

of all the collected fragments, greater than 80% consisted of intact
glomeruli.

The glomeruli were then centrifuged, resuspended in 1 M NaCl

at a concentration equivalent to 10 gm of cortex per ml of solution, and
subjected to ultrasonic disruption.

The insoluble material was then

collected by centrifugation and washed 4 times with 50 ml of 1 M NaCl
followed by 4 washes with glass distilled H2O.

After the last wash, the

basement membrane material was lyophilized and then weighed.
For the preparation of 16aOHE-lysine the dried material

was

resuspended in 2 ml of 50 mM sodium phosphate buffer (pH 7.4) and
reduced with sodium borohydride at a concentration of 0.5 mmoles of
NaBH4

per mg

of

basement

membrane.

After

extraction

with

acetone/ethanol and ethyl ether, the reduced basement membrane was acid
hydrolyzed for 10 hours at a concentration of 1 mg per ml of 6 N HCl.
Purification of 16aOHE-lysine then followed the procedure described
above and outlined in Figure 47.
Amino acid determination.

The amino acid content after hydrolysis

was measured by absorbance at 570 nm after reaction with ninhydrin
(73).

Samples were measured in triplicate and the leucine equivalent

calculated by comparison to a leucine standard curve.
16aOHE-lysine radioimmunoassay.

For each purified protein hydro-

lysate, 20 HPLC fractions (1 ml) were collected.

Each fraction was

redissolved in 0.5 ml of a buffer containing 100 mM NaCl, 50 mM Tris-HCl
pH 8.0, 0.1% gelatin, and 0.01% NaN3.

One hundred microliters of

anti-16aOHE-albumin antiserum (final dilution 1:315,000), which contained 5,000 cpm of C2,4,5,7,16,17-3H]estradiol

(142 Ci/mmole), was then

no.
added to each tube.
12-16 hr.

The samples were mixed and incubated at 4** for

For each assay set, a standard curve was generated by

incubating duplicate samples containing 0.001
authentic 16aOHE-lysine.

to 1.380 pmoles of

The per cent bound was assayed from super-

natants obtained after adding 0.6 ml of a solution of ammonium sulphate
(saturated at 0°), vortexing, and centrifuging for 10 min in an Eppendorf microfuge (Model 5414).

The amount of 16aOHE-lysine present was

calculated from the peak of activity which was found to co-elute with
authentic [3H]16aOHE-lysine (11 min on the HPLC chromatogram). The
absolute content of 16aOHE-lysine was calculated with an HP-97 calculator and a Hewlett-Packard program which performs a log-logit transformation (107) of the radioimmunoassay standard curve.

Background

values were obtained from radioimmunoassay of HPLC fractions after the
injection of a buffer blank.
The recovery of 16aOHE-lysine was estimated by adding [3H]16aOHEalbumin (8 x 10^ cpm, 4-5 uCi/mg) to a membrane preparation which was
then purified concurrently with patient material.

Radioactivity analy-

sis of 5 purifications showed that 31.4% ;^ 3.0% of the starting
['^H]16aOHE-lysine adducts were recovered in the SM-2 eluate.

The

recovery of 16aOHE-lysine from red cell membranes was estimated in
addition, by labelling red cells in vitro with [3H16aOHE.
showed similar yields after purification.

Both methods

The recovery of 16aOHE-lysine

from HPLC chromatography was found to be 90% and was determined by radioimmunoassay of eluted fractions after the injection of 0.4 pmol of
authentic 16aOHE-lysine.

Replicate assays of three red cell preparations

from the same individual yielded an interassay variation of 24%.
Measurement of plasma 16aOHE.

The 16aOHE content of human plasma
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was assayed with modifications of a procedure described previously
(100).

Briefly, one milliliter plasma samples were extracted two times

with 5 ml of freshly opened ether.

The combined ether extracts were

evaporated at 40° under a gentle stream of N2 and the residue dissolved
in 1 ml of ethanol.

This solution was evaporated in a Speed-vac and

redissolved in 0.5 ml of the radioimmunoassay buffer described above. A
0.1 ml solution of antisera (final dilution 1:21,000) which contained
5,000 cpm of [3H]16aOHE (50 Ci/mmol) was then added and the mixtures
incubated at 4" for 12-16 hr.

Antibody bound material was separated

from free material by adding 0.6 ml of 100% saturated solution of
ammonium

sulphate and centrifuging

microfuge.

for 10 min in an Eppendorf

A standard curve was calculated by assaying a duplicate

series of eleven standard solutions containing a range of .006 to 1.75
pmole of 16aOHE.
Patient

selection.

Patients with

Rockefeller University Clinical

SLE were studied at the

Research Center.

Written informed

consent was obtained and all procedures were approved by the Rockefeller
Human Research Committee.

The patients fulfilled the criteria of the

American Rheumatism Association for the diagnosis of SLE.

Normal

volunteers were solicited from the Rockefeller University community.
Normal subjects and patients with SLE were excluded if they were
pregnant or had a history of liver or thyroid disease.

Maternal samples

were from women who were in the third trimester of pregnancy and within
several days of term.

Results
The incubation of 16aOHE with whole blood leads, with time, to its
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incorporation into both plasma proteins and cells (Fig. 42).

In the

case of plasma proteins, the formation of a stable adduct proceeds at a
linear rate which reflects the rate-limiting Heyns rearrangement.

The

incorporation of 16aOHE into red cells initially was assessed by
repeatedly washing the cells.

After an early rapid uptake of steroid,

incorporation was also linear with time and parallel to the rate for the
incorporation of 16aOHE into plasma proteins.
16aOHE into cells presumably

The initial uptake of

is due to the distribution of the

hydrophobic steroid into cell membranes, while the linear rate after 1
hr reflects the rate-limiting Heyns rearrangement of 16aOHE with protein
amino groups.
Table 7 shows the distribution of acid precipitable radioactivity
at 24 hr in the major protein components of the blood.

Fractionation of

the red cells into cytosolic and membrane components demonstrated that
68% of the precipitable L'^H]16aOHE was associated with cytosolic protein
and

32% with membrane protein.

Membrane proteins were found to be

labelled to the highest specific activity, over 15x higher than
albumin.

Evidently, the membrane protein species which are modified by

16aOHE are yery reactive toward the Schiff base and rearrangement
reactions.

The hydrophobic membrane environment probably contributes to

this reactivity by increasing the local concentration of the steroid in
the vicinity of the membrane proteins.
Figure 43 shows the gel electrophoresis and fluorography profile of
plasma which had been incubated with L^H]16aOHE.

All of the detectable

adducts are present on albumin, even when NaCNBH3 is included in the
Incubation mixture.

Electrophoresis of cytosolic proteins

revealed

that all the acid-precipitable radioactivity is due to adduct formation
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Incorporation of [^H]16a-hydroxyestrone into cells

and plasma proteins after incubation with whole blood in vitro.

Figure 43. Electrophoresis and fluorography of
whole plasma labeled with [ H]16a-hydroxyestrone.
Left: Coomassie Blue Staining.
incorporation.

Right: tritium

Plasma Proteins

v^^
^^^
<^^^^^,
^
-HSA

+ - + NaCNBH:*

Figure 44.

Electrophoresis and fluorography of

erythrocyte membrane proteins isolated from
3
erythrocytes incubated with [ H]16a-hydroxyestrone
for 48 hr. Right: Coomassie blue staining. Left:
Tritium incorporation. The numbers in the center
refer to the major erythrocyte membrane protein
components (108).

Erythrocyte Membrane Protei
[^H]l6aOHE

Proteins

•^•tf

+

-

NaCNBHs +
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[3H]16aOHE
Protein

% Bound

fmol 16aOHE/mg protein

Plasma - Albumin

1.5

4.3

Cells - Hemoglobin

0.6

2.7

0.3

63.8

Membrane Protein

Table 7. Distribution of acid-precipitable tritium in the major
protein components of blood after Incubation with [3H]16ahydroxyestrone.
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with hemoglobin (data not shown).

Figure 44 shows the gel electro-

phoresis pattern for erythrocyte membrane proteins.

Proteins modified

by [2H]16aOHE in the absence of NaCNBH3 can be assigned by comparing
this electrophoresis pattern with previously published studies (108).
These include band 1 and 2 (the alpha and beta subunit of spectrin),
proteins in the band 3 region, a protein near or identical to band 4.1,
and membrane-associated hemoglobin.
also labeled.

Several minor protein species are

Small differences in the electrophoretic pattern of

Figure 44 from previously published descriptions of red cell membranes particularly the poor resolution of some bands - are most likely due to
proteolytic artifacts generated in the course of the 24 hr incubation at
370.
In order to examine which membrane proteins form reversible Schiff
bases with 16aOHE, an aliquot of red cells was incubated with [3H]16aOHE
in the presence of NACNBH3.

All potential 16aOHE-protein adducts are

trapped at the level of the Schiff base inermediate and the amount of
['^H]16aOHE incorporation is increased.

Additional proteins which are

labeled under these conditions include band 4.1 and band 5 (actin).
The modification of a small quantitiy of red cell membrane proteins
by 16aOHE suggested that these proteins might be readily analyzed for
16aOHE adduct formation in vivo.

Furthermore, the long half-life of the

red cell (60 days as opposed to 19 days for albumin) would permit a
greater accumulation of adducts with time on erythrocytes than on
albumin.

The availability

of large quantities of red cells from

peripheral blood also would facilitate the analysis of 16aOHE adduct
formation in normal and diseased states.

For these reasons, our efforts

focused on the red cell as a model cell for the study of 16aOHE adduct
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formation in vivo.

Since free 16aOHE is normally present in small

amounts; [6 to 15 pg/ml of plasma (100)] only an immunochemical method
could provide the required sensitivity for the detection of 16aOHE
modified proteins.

As a first step toward this goal, we prepared

antisera to albumin modified by the nonenzymatic addition of 16aOHE.
Figure 45 shows a family of standard curves obtained for four
different antigens utilizing [^Hjestradiol as the competitor.

The use

of tritiated estradiol-173 as the competitor (available at a 3-fold
higher specific activity than [3H]16aOHE), produced an increase in assay
sensitivity.
the

As expected, the greatest inhibition of binding was with

immunogen:

cyanoborohydride

(16aOHE:HSA = 2.7:1).

reduced

16a-hydroxyestrone-albumin

The antisera is probably recognizing neighboring

amino acid determinants in addition to the 16aOHE hapten.
16aOHE showed identical Inhibition curves.

Estradiol and

16aOHE-lysine (the cyanoboro-

hydride product) showed a similar binding curve to that of 16aOHE but
with a slight decrease in inhibition at lower concentrations.

Scatchard

analysis for the binding of 16aOHE revealed a K^ of 5.75 x 10^ M"^ (Fig.
46).

The minimum detectable amount of antigen at the 95% confidence

limit was calculated to be 3.5 pmoles for 16aOHE-albumin, 8 pmoles for
16aOHE, and 20 pmoles for 16aOHE-lysine.
Table 8 summarizes cross-reactivity studies with several steroids
and 16aOHE derivatives.

The complete cross-reactivity of the major

estrogens and 16aOHE-lysine indicates little specificity for structural
changes in ring D.

The antisera is most specific for the estrogen A

ring as all of the nonestrogens exhibited negligible cross-reaction
ranging from <.001%to .004% relative to 16aOHE.

The high specificity

for the phenolic A-ring is further demonstrated by the poor competition
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Figure 45. The relative percentage bound versus log dose curves
for anti-16a-hydroxyestrone-albumin antiserum with four antigens
3
utilizing [ HJestradiol as the competitor. Each point represents
the mean of duplicate determinations.
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Figure 46. Scatchard plot of anti-16a-hydroxyestrone-albumin antiserum for the binding of
16a-hydroxyestrone.
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COMPOUND

% CROSS REACTIVITY AT 50% BINDING

16a-Hydroxystrone (16aOHE)
17B-Estradiol
Estriol
Estrone
2-Hydroxyestradiol

100
100
100
108

16aOHE-lysine (NaCNBH3 product)
16aOHE-peptides (NaCNBH3 product)
16aOHE-albumin (NaCNBH3 product)
16aOHE-albumin (Heyns product)

100
99
124
52

Dehydroepi androsterone
Progesterone
Etiocholanolone
Cortisol
Prednisone

0.008

0.004
0.003
0.002
<0.001
<0.001

Table 8. Percent cross-reaction relative to 16ahydroxyestrone of anti-16a-hydroxyestrone-albumin
antiserum with selected compounds.
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of 2-hydroxyestradiol, which differs from estradiol in possessing an
additional hydroxyl group at position 2.
Tryptic

peptides

prepared

from

NaCNBH3 reduced 16aOHE-albumin

showed the same degree of inhibition as 16aOHE-lysine, but less than
16aOHE-albumin, evidently reflecting the loss of tertiary structure
determinants adjacent to the 16aOHE hapten.

Interestingly, the 16aOHE-

albumin Heyns product, which had 1 mole of 16aOHE per mole of albumin,
inhibited binding less than did NaCNBH3 reduced 16aOHE-albumin.

This

may reflect the fact that the reactive lysine involved in the Heyns
rearrangement lies in an obscured pocket and the 16aOHE adduct which
forms with it is not completely accessible to binding by the antibody.

The detection of 16aOHE-lysine adducts formed in vivo necessitated
the analysis of a large quantity of protein.

Therefore, a method was

developed for the purification of 16aOHE-lysine adducts away from free
amino acids and non-polar steroids.
47.

This scheme is outlined in Figure

Erythrocyte membranes are prepared and reacted with an excess of

NaBH4.

Sodium borohydride reduces the 16-keto group of the Heyns

product, generating an adduct which is stable to acid hydrolysis and
structurally similar to the NaCNBH3 product.

The reduction is then

quenched and the membrane lipids extracted in a single step by adding
nine volumes of acetone/ethanol (1:1).

The membrane protein pellet is

then subjected to acid hydrolysis in order to generate free amino acids
and their derivatives, including 16aOHE-lysine.

Ether extraction after

acid hydrolysis removes any additional lipid soluble material which
interferes

with

the succeeding

hydrophobic

chromatography

step.

Estrogens, the only known molecules which cross-react significantly with
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Crude Membranes
NaBH4 Reduction
EtOH-Acetone Extract
Lipids
Membrane Proteins
Acid Hydrolysis
Amino Acids & Derivatives
Ether Extract

-•Discard

Phenyl Sepharose
Chromatography

V
. 4 M NaCl
1 m M NaP04 *^

*«»:«« A^irjo
• Ammo Acids

SM-2 Chromatography

V ImM

NaP04
-•Discard

50% MeOH
HPLC Fractionationyy "YV
Radioimmunoassay

Figure 47. The flow scheme for the purification of
16a-hydroxyestrone-lysine from membrane proteins.
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the antibody, are removed by the two organic extractions.
Utilizing

synthetic

chromatographic

[3H]16aOHE-lysine

methods were attempted

16aOHE-lysine from the hydrolysate.

as a standard,

several

in an effort to purify

16aOHE-lysine absorbed to charcoal

(Norit-A), but could not be eluted with either methanol or ethanol
containing 2 M NH4OH or 2 M pyridine.

Chromatography in the amino acid

system of Moore et al.(104) utilizing a Beckman Type W-2 resin was
unsuccessful as 16aOHE-lysine was eluted only with the 0.2 M NaOH
regeneration

step.

Similarly, cation-exchange

chromatography on a

sulfonic-acid-polystyrene resin (Bio-Rad AG50W-X8) was hampered by the
nonspecific absorption of 16aOHE-lysine onto the solid support.
Specific elution of 16aOHE-lysine under mild, aqueous condiitons
was

finally

achieved

phenyl-Sepharose.
in

NaCl.

At

with

a

chromatography

system

employing

The pH of the hydrolysate is neutralized and made 4M

this

ionic

strength,

16aOHE-lysine

absorbs

to

phenyl-Sepharose while amino acids are eluted. 16aOHE-lysine is then
removed by lowering the ionic strength.

Fig 48 shows the elution

profile of a hydrolysate of membrane proteins modified by incubation
with [3H]16aOHE.

Chromatography of a hydrolysate of C3H]16aOHE-albumin

produces an identical pattern.

Tyrosine and other amino acids elute as

shown and [3H]16aOHE-lysine elutes with 1 mM sodium phosphate buffer.
From an analysis of three [3H]16aOHE-albumin hydrolysates, it was found
that 32+4% of the starting [3H]16aOHE adducts survive acid hydrolysis
and

are

recovered

[2H]16aOHE-lysine

in

this

fraction.

product was confirmed

reverse-phase HPLC with authentic

The

identity

of this

by its co-elution

[3H]16aOHE-lysine.

under

Of the total

tritium applied to the phenyl-Sepharose column, an additional 20% can be

-300

- 200

1
E
O

- IOO

0

8
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16

20

24

0

Elution (ml)

Figure 48.

The elution profile of a membrane protein
3
hydrolysate from red cells incubated with [ H]16aOHE
and chromatographed on phenyl-Sepharose. A and B show
the elution positions of tyrosine and 16aOHE, respectively.
The horizontal bar indicates the fractions pooled for
SM-2 chromatography.
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eluted with 50% methanol.
all the remaining

Further washing with 10% SDS removes almost

radioactivity

(38%).

Analysis of these later

fractions by HPLC showed several radioactive peaks, none of which
coeluted with 16aOHE-lysine.
The 16aOHE-lysine containing fraction is then rechromatographed
over a column of SM-2 resin (Fig. 49). The majority of the material
absorbing at 280 nm is removed in the Initial 1 mM sodium phosphate
buffer wash.

16aOHE-lysine is eluted with methanol/water (1:1, v/v) and

is now present in a volatile solvent with a minimun of solute.

The

recovery of 16aOHE-lysine from this resin is 100%, as assessed by
chromatography of the [2H]16aOHE-albumin hydrolysate.
The purified material

was subjected

to radioimmunoassay

and

measurable binding activity was detected in all the red cell extracts
tested.

Fractionation of the purified hydrolysates by reverse-phase

HPLC showed that all the erythrocyte preparations had antibody binding
activity which co-eluted with the 16aOHE-lysine standard.

Figure 50

shows representative antibody binding profiles of samples from three
individuals.

These were generated by injecting 0.1 ml of the SM-2

eluate (equivalent to 0.2 ml of packed cells) and collecting 1 ml column
fractions for radioimmunoassay.

Figure SOB is the chromatogram of a

[3H]16aOHE-membrane hydrolysate fractionated in the same manner as in
Figure 50A and counted in a liquid scintillation counter.

Fig SOC shows

the integrated radioactive flow profile of an authentic [3H]16aOHElysine

standard.

The

radioactivity

hydrolysate co-chromatographs

with

of

the

the

[3H]16aOHE-membrane

[3H]16aOHE-lysine

standard,

indicating that 16aOHE-lysine is the only acid-stable adduct generated
by the modification in vitro of erythrocytes with 16aOHE.

The three

r200
- 150
- IOO
o
- 50
0
4
8
12
Elution (ml)

Figure 49. The SM-2 chromatographic profile
3
of the [ H]16aOHE-lysine containing fraction
isolated previously by phenyl-Sepharose
chromatography.
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Figure 50.

Reverse^phase HPLC fractionation of purified mem-

brane protein hydrolysates. A: The relative percentage bound
as measured by radioimmunoassay for 1 ml fractions of three
hydrolysates. B: Fractionation of a hydrolysate of cells
incubated with [^H]16aOHE. C: Authentic [^H]16aOHE-lysine.
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erythrocyte preparations shown in Figure 50A all have antibody-binding
peaks which co-elute with 16aOHE-lysine.

Additional

products with

binding activity are present in two of the extracts and elute in a more
polar region of the chromatogram.
unknown.

The identity of these products is

It is unlikely that 16aOHE is modifying an additional amino

acid since the incubation of [2H]16aOHE with erythrocytes in vitro
produces only [3H]16aOHE-lysine.

Perhaps, once attached to protein.

16aOHE is oxidized or metabolized in the course of the red cell life,
producing an adduct which is more polar and continues to cross-react
with the antisera.

Covalent estrogen lysine adducts might also result

from the reaction of the minor estrogens 16 3-hydroxyestrone

and

16-ketoestradiol.
Figure 51 shows the 16aOHE-lysine values obtained for erythrocyte
membrane proteins from the different groups of individuals studied.

On

the left abscissa, the values are expressed as a specific activity of
16aOHE-lysine per leucine equivalent of hydrolyzed membrane protein.
The right abscissa expresses this value in terms of the average amount
of 16aOHE-lysine adducts on a single erythrocyte.

Table 9 lists the

mean value and standard error of the mean for each group shown in Figure
51.

The data show that there is a significant elevation

in

16aOHE-lysine content in maternal and SLE women when compared to normal
women.

The mean level of 16aOHE-lysine in the maternal red cell is

higher than in the SLE patient but, as a group, the individual points
also show a wider distribution.

The mean 16aOHE-lysine value in the

male SLE patients also appears to be higher than in the control male
group, but this mean reflects only four points and is not statistically
significant (P <.15).
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Figure 51. Erythrocyte membrane 16a-hydroxyestrone-lysine
levels in normal, SLE, and Maternal subjects. The horizontal bar indicates the mean value within each group.
(f) : females, (o) : males.

16aOHE-lysine levels in erythrocyte membrane proteins

Number

16aOHE-lysine*

P

7

5.2 + 1.1

11

15.7 + 4.1

<.05

Maternal

9

24.9 + 6.2

<.01

Normal male

7

7.1 + 1 . 8

SLE male

4

14.7 + 8.6

Normal female
SLE female

*pmoles 16aOHE-lysine/mmole leucine equivalents.
Mean + 1 S.E.M.

Table 9. Summary of Figure 51 data.
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Women with SLE and women in the third trimester of pregnancy
therefore, have significantly higher levels of red cell 16aOHE-lysine
adducts than normal controls.

The maternal state is associated with a

gradually increasing plasma 16aOHE level which peaks during the third
trimester at about 2.8 pmole/ml and then rapidly falls off (109).

The

red cell associated 16aOHE-lysine adducts presumably accumulate during
this rapid elevation of plasma 16aOHE.

The SLE females show a red cell

16aOHE-lysine value which falls between the normal and maternal
population means.

Plasma 16aOHE levels are only moderately elevated in

most patients and fluctuations in these levels have been observed to
occur with time (110).
Since the life of the red cell is 120 days, this cell would be
expected to act as an integrator to provide, over an extended period, a
time average of the 16aOHE status of a person.

It is apparent from the

red cell data however, that there is some variation in the levels of
16aOHE-lysine present.
due to several reasons.

In the case of the maternal data, this could be
Variations in the absolute plasma content of

16aOHE or its rate of increase during the second trimester would effect
the cumulative exposure of the cell to 16aOHE.

Lysine adducts involving

the minor estrogens 16 30HE and 16-keto-estradiol may also be present
during pregnancy and might not be distinguishable from 16aOHE-lysine in
the assay.

In the case of the SLE group, the

presence of a low-grade

hemolysis would decrease the red-cell lifetime and cause variability in
the level of 16aOHE-lysine.

The susceptibility of red cell proteins to

modofication also may vary in Individuals, perhaps as a result of
genetic differences in the composition of reactive proteins in the
membranes.
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The patients with SLE which were studied had a varied clinical
history.

There was no statistical correlation between the 16aOHE-lysine

values in the red cell and clinical parameters such as erythrocyte
sedimentation rate, hemolytic complement, and anti-nuclear or anti-DNA
antibodies.

Furthermore, there was no relation between 16aOHE-lysine

and patient age or the degree of glucocorticoid therapy.
An attempt was made to correlate the extent of protein modification
by 16aOHE in the red cell membrane with the level of plasma 16aOHE
measured at the time the blood was sampled.

A regression plot of plasma

16aOHE versus red cell 16aOHE-lysine is shown in Figure 52 for normal
and SLE patients.

There is a linear correlation (r = 0.55, P<.0025) for

this data although a number of points fall outside the 95% confidence
limits.

Maternal values are not plotted since the high estriol values

associated with pregnancy interfere significantly with the radioimmunoassay for free 16aOHE (100).
The fact that a number of points fall outside the 95% confidence
interval however, indicates that the measurement of one parameter is
only of limited value in predicting the value of the second parameter.
Since the plasma 16aOHE level represents one measurement in time, while
the 16aOHE-lysine content is an integral value reflecting a long time
period, variation in the correlation may be the result of periodic
fluctuations in the plasma content of 16aOHE.

This has been observed to

occur, particularly

In addition, recent

in SLE patients

(110).

experiments indicate that significant levels of 16aOHE are present in
the plasma in the form of the 3-sulphate (111).

Lysine addition

products could form with this metabolite and would be detected in
16aOHE-lysine assay.

The level of reactive

plasma 16aOHE however.
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would be underestimated because the 16aOHE radioimmunoassay does not
detect the sulfate derivative.
We next applied the assay for 16aOHE-modification to proteins
obtained from a membrane preparation of lymphocytes isolated from
peripheral

blood by Ficoll

density gradient centrifugation.

The

lymphocyte is of interest because it is a much longer lived cell than
the erythrocyte

(112) and an intriguing possibility exists that

increased plasma levels of free 16aOHE might lead to an increased
modification of lymphocyte cell surface proteins and cause immune
dysfunction.

Figure 53 shows the levels of 16aOHE-lysine measured in

lymphocyte membranes from normal controls and patients with SLE.

There

is a significant elevation of 16aOHE-lysine in women with SLE when
compared to normal women (Table 10). The measurement of a single male
SLE value which was obtained is also shown.

Of significance is the fact

that the level of protein modification within the lymphocyte is three
times higher than for the red cell in each of the groups studies.
Within each group, there is also a greater variation in the lymphocyte
16aOHE-lysine values than in the red cell.

In the SLE group, there was

no correlation between the level of lymphocyte protein modification and
any objective clinical parameter.
The mean level of 16aOHE-protein modification within lymphocytes
was three times higher than in the red cell for the normal and the SLE
subjects studied.

These values most likely reflect the longer circu-

lating life of the lymphocyte; for example, a mean lifespan of 530 ;^ 64
days has been reported (112).

In addition, women with SLE were found to

have significantly higher levels of 16aOHE-lysine adducts than normal
women.

The levels of 16aOHE-lysine also showed a wider distribution
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SLE

Lymphocyte membrane 16a-hydroxyestrone-lysine

levels in normal and SLE subjects. The horizontal bar
indicates the mean value within each group. (•) : females.
(o) : males.

16aOHE-lysine levels in lymphocyte membrane proteins

Number

16aOHE-lysine*

P

6

15.6 + 3.4

-

11

40.5 + 5 . 4

<.005

Normal male

8

20.7 + 4.2

SLE male

1

38.4

Normal female
SLE female

*pmoles 16aOHE-lysine/mmole leucine equivalents.
Mean + 1 S.E.M.

Table 10. Summary of Figure 53 data.
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than in the red cell.

Variation in the turnover of membrane proteins or

in the lifespan and content of different lymphocyte subsets, particularly with the SLE group, might be a factor contributing to the wide
distribution of 16aOHE-lysine values.
An extremely long-lived extracellular protein which has been found
to accumulate the products of nonenzymatic glycosylation over the age of
the whole organism is collagen (113).

Reasoning that 16aOHE-adducts

might accumulate similarly on collagen, the presence of these adducts
was assayed on four preparations of glomerular basement membrane.
results of these determinations are shown in Table 11.
selected that were close in age and sex-matched.

The

Samples were

The values for both of

the normal individuals are over one order of magnitude higher than the
mean 16aOHE-lysine value found in the normal

red cell.

This is

presumably due to the extremely low turnover rate of collagen.

Of the

SLE kidneys, sample A was from a patient with a 12 year history of SLE
and a 9 year history of glomerulonephritis.

Sample B was obtained from

a patient with a thirty-year history of SLE and an 8 year history of
nephritis.
The SLE kidneys were found to have higher levels of basement
membrane 16aOHE-lysine than age and sex-matched normal controls.

Data

on either the plasma 16aOHE level or the rate of 16a-hydroxylation was
not available for the patients in this group.

It is noteworthy,

nevertheless, that the patient with the highest levels of 16aOHE-lysine
(256 +_ 61) had SLE for 30 years and an 8 year history of nephritis.

It is clear from this data that the level of protein modification
by 16aOHE increases with the lifespan of the protein.

Table 12

16aOHE-lysine values in the glomerular basement membrane

Normal female

SLE female

Age

16aOHE-lysine*

A

50

86 ^ 20

B

60

129 + 31

A

49

B

50

102 + 24
256 + 61

*pmoles 16aOHE-lysine/mmole leucine equivalents.
Mean + 1 S.E.M.

Table 11.
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16aOHE--Iy;sine*

SLE

Protein

Normal

Erythrocyte membrane

5.2

15.7

120 d.

Lymphocyte membrane

15.6

40.5

- 530 d.

107

179

many years

Basement membrane coll agen

Mean Lifespan

*mean, pmoles/mmole leu. equiv.

Table 12. Summary of 16aOHE-lysine levels in different proteins.

summarizes the mean values of 16aOHE-lysine measured in different
proteins in both normal individuals and patients with SLE. For each
protein, the level of modification appears proportional to its
biological lifespan.

In relative terms, the level of modification for

each type of protein is increased in SLE patients.

This is consistent

with the idea that 16aOHE adducts accumulate over a long time period,
and that the degree of protein modification is a time integral of the
free 16aOHE level.
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C.

Studies of Anti-estrogen Autoantibodies.

Since SLE patients produce a diversity of antibodies to selfantigens, a reasonable possibility is that autoantibodies may also be
present against endogenous 16aOHE-lysine adducts.

The existence of

autoantibodies would also indicate that 16aOHE-modified proteins are
recognized by components of the immune system.
In order to detect the occurence of these anti-estrogen antibodies,
an enzyme-linked immunoassay was developed.

The following section

describes this assay, the detection of anti-estrogen antibodies in oral
contraceptive users, and preliminary studies of the anti-estrogen
antibody activity in patients with SLE.

Methods
Reagents. Agarose immobilized 17 3-estradiol, 17-hemisuccinate (100
ml) was custom synthesized by Pierce Chemical Co. using 6% crosslinked
di aminopropyl amine agarose as the solid support.

Estradiol content was

found to be 26 ^mole/ml resin and was derived from the extinction at 280
nm of acid hydrolyzed resin (1 N HCl at 60° for 5 min). The amount of
linked estradiol was then calculated by comparison to a standard curve
generated from the acid hydrolysis of unmodified agarose to which free
estradiol had been added.

The resin was washed extensively with a

buffer containing PBS, 0.05% Tween-20 (Biorad Laboratories), and 3 mM
NaN3.

Alkaline phosphatase linked anti-human IgG (H & L chain) was from

Cappel Laboratories (Cochranville, PA).
Assay Procedure.
Millipore filter.

All buffers were filtered through a 0.45 nm

Prior to analysis all plasma samples were centrifuged
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for 1 min in an Eppendorf microfuge (Model 5414) to remove insoluble
material.

The plasma supernatant was then diluted 1:40 in a buffer

containing PBS, 0.05% Tween-20, and 3 mM NaN3 and filtered through a
0.22 nM Milex filter unit.

0.4 ml was then added to 0.1 ml of a 25 %

solution of estradiol-agarose and incubated at room temperature with
gentle rocking for 12-16 hr.

At the end of this time, the resin was

washed 4 times with 1 ml of PBS-Tween.

0.5 ml of a solution of

anti-human IgG (diluted 1:500 in a buffer containing 0.9 M NaCl, 10 mM
NaP04, pH 7.4, 0.05% Tween-20, and 3 mM NaN3) was then added and the
mixture incubated with gentle rocking for 6 hr.

The second antibody was

then removed and the resin washed 4 times with 0.9 M NaCl, 10 mM NaP04,
pH 7.4, 0.05% Tween-20, and 3 mM NaN3; and 2 times with 10 mM diethanolamine, pH 9.0, and 3 mM NaN3.

0.5 ml of p-nitrophenol phosphate

(Sigma), dissolved in 0.1 M di ethanol amine pH 9.8 with 3 mM NaN3, was
then added and the mixtures incubated at room temperature.

At the end

of 30 min, the reaction was terminated by adding 0.2 ml of 1 M NaOH.
The resin was then removed by centrifugation and the absorbance of the
supernatant recorded at 400 nm.
Patient Selection.

Patients with SLE were selected by the same

criteria as described on p. 111.

The non-SLE patients Included males

and females with rheumatoid arthritis (n = 7 ) , osteoarthritis (n = 4 ) ,
primary biliary cirrhosis (n = 11), scleroderma (n = 3 ) , Sjogren's
syndrome (n = 1 ) , mixed connective tissue disease (n = 1 ) , polymyositis
(n = 1 ) , tenosynovitis (n = 1 ) , hypergammaglobulinemia
agammaglobulinemia (n = 1 ) , and multiple sclerosis (n = 1).

(n = 1 ) ,
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Results
An outline of the immunoassay for anti-estrogen antibodies is shown
in Figure 54. Analysis of a number of control plasmas at arbitrary
dilutions revealed that many disease-free normal women had antibodies
which bound to estrogen-linked-agarose beads.

This result was puzzling

until it was realized that all of the women who displayed this activity
had at some time been users of oral contraceptives.

Figure 55

summarizes results obtained for normal plasma assayed at a final
dilution of 1:50.

Approximately 30% of women with a history of oral

contraceptive use displayed activity of greater than 0.2 O.D. on this
assay.
The occurence of anti-estrogen antibodies in oral contraceptive
users has been reported previously by Beaumont et al. (114-116).

Using

an assay base on the specific binding of 17a-[3H]ethinylestradiol

(the

estrogen component of oral contraceptives), they observed circulating
anti-ethinyl estradiol antibodies in oral contraceptive users, but not in
non-users.

In a number of cases these antibodies were present years

after the discontinuation of birth control medication (114).

Among the

positive values shown in Figure 55, several were from women who had not
been on birth control medication for 2 to 8 years.
In further studies, the Beaumonts observed a significant correlation between circulating immune complexes, the presence of antiethinylestradiol antibodies within these complexes, and the occurence of
vascular complications among oral contraceptive users (115).

Although a

definitive role for immune complexes in thrombosis has not been established, they propose that these antibodies and their associated immune
complexes may, over a long period of time, be the factor contributing
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Figure 54. Schematic outline of the enzyme-linked immunoassay
for anti-estrogen antibodies.
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Figure 55. Anti-estrogen antibody activity in normal,
disease-free males and females. 00+ : denotes a
history of oral contraceptive use.
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to the increased risk of thrombosis and vascular disease present in
women who have been on birth control pills for many years.
The estrogen which is common to all estrogen containing birth
control

pills is the synthetic analog, 17a-ethinylestradiol.

The

ethinyl function serves to increase the oral potency of this derivative
by Inhibiting

oxidation and conjugation of the estrogen

D-ring.

Ethinylestradiol can undergo enzymatic conversion to metabolites which
form covalent adducts with proteins; leading to haptens which could
stimulate antibody production.
enzymatic activation.

Figure 56 shows two possible routes of

The 2-hydroxylase pathway is believed to be the

major metabolic route because 16-hydroxylation, the alternate pathway,
is blocked by the presence of the ethinyl function.

The resulting

catechol derivatives can undergo oxidation to yield semiquinones and
qui nones which readily add to protein amino or sulfhydryl groups.

A

number of studies have indicated that this route results in the
formation of covalent estrogen-protein adducts in the liver (117, 118).
The pathway produced by the action of cytochrome P-450 has been
partially

defined.

There

is evidence

for the formation of an

unsaturated epoxide at the ethinyl function , which probably leads to
the binding and inactivation of P-450 and the generation of hepatic
"green pigment" (119).

Epoxide formation is also believed to be the

step in the generation of the metabolite D-homoestrone (120).

It is

likely that the unsaturated epoxide also would react with nucleophilic
groups in proteins to yield estrogen adducts linked in the steroid
D-ring.

Since the D-ring conjugated product is antigenically similar to

the agarose immobilized estrogen, the P-450 product is probably the one
which induced the anti-estrogen antibodies detected in the immunoassay.
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Figure 57 shows the preliminary results of SLE plasma assayed for
the presence of anti-estrogen antibodies.

The left side shows male and

female values obtained from patients with autoimmune or rheumatic
disease other than SLE.

A few male and female SLE patients display

activity on this assay without ever having been on oral contraceptives.
This activity may represent an antibody formed to the endogenous
16aOHE-lysine adduct or alternatively, an autoantibody elicited in
response

to

another

cross-reactive

antigen.

The

pathological

significance of these estrogen reactive antibodies awaits further study.
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D.

Conclusion.

In analogy to Cortisol and the glucocorticoids, the ketolic
estrogen 16a-hydroxyestrone can react with the lysine residues of
proteins to form stable, covalent addition products.

These adducts can

be detected in vivo on the membrane proteins of the erythrocyte and the
lymphocyte and the long-lived structural protein collagen.

The level of

protein modification by 16aOHE Increases with the lifespan of the
protein.

Furthermore, conditions such as pregnancy and SLE, in which

increased levels of free 16aOHE occur, also are associated with
increased protein modification.
Proteins modified by the nonenzymatic addition of 16aOHE can be
antigenic, and 16aOHE modified albumin was used to prepare the antisera
used in the radioimmunoassay of 16aOHE-lysine.

In vivo, it appears that

one example of a protein bound estrogen, produced by the metabolism of
17a-ethinylestradiol,

leads

to anti-estrogen

antibodies

receiving this steroid for oral contraception.
also display an anti-estrogen antibody activity.

in women

Some patients with SLE
These antibodies may

represent a cross-reactive autoantibody or perhaps, be produced in
response to the increased levels of endogenous 16aOHE-protein adducts
which are present in these patients.
The role of 16aOHE-protein adducts in either the etiology or the
pathology of SLE has not yet been defined.

These adducts may in fact

stimulate autoantibody production in some Individuals.

It is also

possible that 16aOHE can trigger immune dysfunction by reacting with
immunoregulatory membrane proteins and disrupting cellular interactions.
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5. Nonenzymatic Modification of DNA by Reducing Sugars.
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A.

Biochemical and Genetic Studies of DNA modification in Prokaryotic
Systems.

The demonstration that proteins undergo nonenzymatic glycosylation
in vivo and that protein-bound Maillard products occur on long-lived
structural proteins led to the hypothesis that nucleic acids might also
undergo chemical modification by reducing sugars.

Because nucleic acids

are long-lived molecules in the resting cell, the accumulation of stable
addition products with time would affect the viability of the genetic
material.

Current theories of aging emphasize the concept of "error

catastrophe" and that the functional

decrements characteristic of

cellular senescence are due to the progresssive accumulation of
unrepaired genetic lesions (121, 122).

Age-dependent changes in the

genetic material are well-documented and Include increased tumorigenesis
(123), chromosomal aberrations (124), DNA strand breaks (125), and
decreases in DNA repair (126), replication (127), and transcription
(128).

Interestingly, there are two age-related phenomena which are

exacerbated by the diabetic state; the decreased replicative capacity of
the aged fibroblast and the increased frequency of abnormal births seen
with the increasing age of the mother (129, 130).
The following studies show that the primary amino groups of
nucleotides can react nonenzymatically with sugars to produce spectral
changes, abnormalities in DNA template function, and mutagenesis.

Methods
Spectroscopic

studies.

Solutions

(1 ml) were prepared that

contained 10 mM deoxyribonucleotide (Sigma) and 150 mM glucose-6-
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phosphate (G6P, Calbiochem) or glucose (Baker) in 50 mM Hepes/0.5 mM
EDTA, pH 8.0, adjusted with NaOH.

All solutions were sterilized by

filtration through a Millex filter prior to incubation at 37° in the
dark.

Control solutions contained sugar alone or nucleotide alone.

DNA

incubation mixtures contained calf-thymus DNA (Sigma) at 2 mg/ml.
Single-stranded DNA (ssDNA) was generated by boiling DNA for 5 min and
then rapidly cooling the solution on ice.

At the end of 4 days, the

solutions were diluted 1:1 with distilled H2O and the visible and UV
spectra recorded on a Hewlett-Packard model 8450A sepectrophotometer.
Fluoresence measurements were made on a Perkin-Elmer model 204
fluorescence spectrophotometer.

Incubation mixtures showing absorbance

changes were diluted 1:6 with distilled H2O, and the excitation and
emission maxima were determined by preliminary

scanning.

Final

recordings were made at an excitation wavelength of 315 nm and an
emission wavelength of 420 nm.

Fluorescence spectra of modified

nucleotides and DNA were determined by subtraction of the background
fluorescence generated by G6P degradation (131), which occurs during
prolonged incubation.

DNA and nucleotides incubated without G6P did not

exhibit measurable fluorescence.

The magnitude of the quantum yield was

calculated with reference to the emission at 442 nm of a standard
solution of quinine (10 ^M in 0.05 M H2SO4) excited at 315 nm
(132).
DNA Transfection.

Bacteriophage fl DNA was isolated by phenol

extraction of concentrated phage particles.

Each transfection assay

mixture contained 2 ng of DNA in 0.1 ml of sterile solution of 50 mM
Hepes buffer, pH 8.0, and 0.5 mM EDTA and either glucose or G6P.
Control

Incubation mixtures contained either DNA or sugar alone.
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After incubation at 37° in the dark, duplicated aliquots were
transfected into 0.3 ml of a suspension of calcium chloride-treated
Escherichia coli

(strain K38) (133).

Plaque-forming

units were

quantified after an overnight growth.
DNA Electrophoresis.

DNAs were electrophoresed in 1% agarose gels

under alkaline conditions (30 mM NaOH) sufficient to separate linear
from covalently closed DNA (134).

After neutralization, the gel was

stained with ethidium bromide at 1 ug/ml.

For detection of 66P

incorporation, 4 uCi of D-[l-l^C]glucose 6-phosphate (50 mCi/mmol; New
England Nuclear) was incubated with 16 ug of purified fl DNA for 2 weeks
as described above.

Radiochemical purity was assessed by HPLC using a

Ci3 column (Waters Associates) and a mobile phase of 20 mM potassium
phosphate buffer (pH 5.5) containing 2% methanol that increased linearly
to 20% methanol from 0 to 20 min (135).

At the end of the incubation

period, 8 ug of DNA was loaded per lane and electrophoresed, and the
gels were impregnated with EN^HANCE (New England Nuclear).

Flourography

was for 4 weeks at -80°.
Mutagenesis Assay.

Purified pBR322 DNA (1 ug) was incubated at 37°

under sterile conditions with 150 mM to 400 mM G6P in 0.2 ml of buffer
containing 50 mM Hepes (pH 8.0) and 0.5 mM EDTA.
lacked G6P.

Control incubations

At the indicated times, 0.3 ml of a CaCl2 treated E.coli

strain K38 was transformed with 5-20 ul aliquots of the incubated
solutions.

Cells were plated onto ampicillin supplemented TY plates (50

ug/ml) and colonies enumerated after overnight growth.

Colonies

selected for amp'^ were then replicated onto tetracycline containing
media (20 ug/ml) and the presence of tet^* assessed.
Southern Hybridization.

A stab from an isolated single colony was
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inoculated into 40 ml of tryptone broth and harvested after bacterial
growth reached an OD66O of 1-1.4.

Whole E. coli DNA was prepared by the

method of Smith (136), and DNA content determined by absorbance at 260
nm.

Six ug of DNA was electrophoresed in each lane of a 0.6% agarose

gel (TBE and ethidium bromide, (137)), and run until the bromophenol
blue marker dye had migrated 14 cm.

The gels were washed in 0.25 N HCl,

processed for Southern transfer, and blotted onto Gene Screen Plus (New
England Nuclear) by capillary transfer following the methods recommended
by the manufacturer. Staining of the transferred gels with ethidium
bromide demonstrated that all of the DNA had transferred to the
hybridization membrane.

The membranes were then washed by shaking at

370 with a pre-hybridization solution containing 50% formamide, 5x SSC,
Ix Denhardt's solution (137), 1% SDS, and 0.1 mg/ml denatured salmon
sperm DNA.

After 6 hr, IxlO^cpm (Cerenkov) of a nick-translated (137)

32p-iabelled probe (2.4x10^ cpm/ug) was added and hybridization allowed
to proceed for 12 hr.

The hybridization membranes were then washed

three times at room temperature in 0.2x SSC, 1% SDS, and 0.1 % sodium
pyrophosphate followed by two washes at 65° in 0.5x SSC and 1% SDS. The
membranes were then air-dried and exposed to x-ray film for 4 hr at -80°
in the presence of intensifying screens.

Results
Although the Maillard reaction is characteristically a slow process,
studies with proteins have shown that modification occurs as an integral
function of time and sugar concentration (138).

As a first step toward

the study of DNA modification by sugars therefore, individual nucleotides
and purified DNA were incubated at 37° with high concentrations of
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either glucose or G6P.

As shown in Figure 58, 4 days of incubation with

G6P was sufficient to produce absorbance changes in the 300 - 400 nm
range that are similar to those described for the nonenzymatic browning
of proteins (139, 140). No changes were detected in the 220 to 300 nm
region.

The enhanced browning effect of G6P - in contrast to glucose,

which did not show any effect under these conditions - is consistent
with the observation that phosphorylated sugars glycosylate proteins
more readily than nonphosphorylated ones (141), and at a rate which is a
function of their reducing action (142).

Of significance is the fact

that negligible spectral changes occured with TMP, the only nucleotide
lacking a primary amino group, and with double-stranded DNA (dsDNA),
presumably because hydrogen bonding hinders the reaction of the amino
groups with G6P.
Flourescence spectra were obtained for the chromophores produced by
incubation of ss DNA and the nucleotides AMP, CMP,and GMP with G6P;
excitation and emission spectra (uncorrected) are shown in Figure 59.
Excitation in the 250 to 270 nm region, where nucleotides absorb
strongly, produced neither new nor significant emission.

Instead, the

chromophores produced had excitation maxima at 315 nm with calculated
quantum yields of 2.37 x 10-2 for GMP, 1.15 x 10-2 for AMP, and 1.9 x
10-3 for CMP. AMP showed in addition, a large second excitation maximum
at 360 nm.

CMP and ssDNA had smaller excitation maxima in the 330 to

350 region.

As shown in Figure 59, excitation at 315 nm produced

emissions that ranged from 350 to 600 nm.
We next investigated the biochemical effects of glucose and G6P on
DNA from the E. coli bacteriophage f 1.

fl DNA is a single stranded,

covalently closed circle composed of 6470 nucleotides (143).

The
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properties of the DNA examined included its transfection potential into
the host strain K38 and its structural Integrity as analyzed by alkaline
gel electrophoresis.

DNA was isolated from the virus by phenol

extraction and Incubated with different concentrations of sugars for
eight days at 37^.

At the end of this time, aliquots were removed and

transfected into the calcium chloride-treated E.coli.
The percentage decrease in the transfection efficiency of glucose
and G6P treated DNA relative to that of DNA Incubated without sugar is
shown in Figure 60.

DNA exposed to G6P showed a dramatic decrease in

transfection efficiency; incubation with 150 mM G6P decreased the value
by 4 orders of magnitude.

The rate of loss of biological activity was

first order with respect to sugar concentration.

Glucose caused a much

smaller decrease in transfection efficiency; at 150 mM, efficiency was
reduced to ~33% of control.
The following experiment was carried out to test for the
possibility that the carbohydrate alone, or the products of spontaneous
carbohydrate degradation, could inhibit expression of the viral genome.
Glucose and G6P (150 mM) were incubated for 8 days and equivalent
amounts were added to calcium chloride-treated E. col 1 together with
untreated fl DNA.

As shown in Figure 60, these conditions produced only

a small (<50%) inhibition of transfection.
Controls for the G6P inhibitory effect were also carried out.

The

possibility that trace metals might be present in the G6P solution and
catalyze DNA degradation was tested by treatment with the resin Chelex
100.

Similarly, the presence of any contaminating DNA nucleases was

diminished by filtering th G6P solution through a dialysis membrane (M^
cutoff 3,500).

The effects of these treatments were insignificant
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(Fig. 60).
fl DNA from the incubation mixtures was subjected to gel
electrophoresis under conditions that separate covalently closed DNA
from DNA in a linear form.

Linear DNA would result from a single nick

in the phosphodiester backbone of the circular DNA.

Figure 61 shows

that there is a concentration-dependent strand scission that occurs in
the course of incubation with G6P.

With increasing amounts of G6P

(lanes 3-6), the proportion of DNA in the circular form decreases as the
amount of linear form increases.

At yery high 66P concentrations (lanes

5 and 6 ) , the closed circular DNA disappears and increasing amounts of
low molecular weight DNA fragments become visible.

Control incubations

without sugar (lane 2) or with glucose (lanes 7 and 8) show only a
slight increase in linear DNA when compared with unincubated DNA (lane
1). A similar progression of strand scission was observed with G6P
purified by ultrafiltration.
Electrophoresis and fluorography of fl DNA incubated with [14c]G6P
showed that ^^C is incorporated both into intact closed circular DNA as
well as into linear DNA (Fig. 62). Thus, the formation of a G6P
addition product precedes the event which leads to strand breakage.
Figures 60 and 61 shows that stand scission also must occur at a rate
slower than the rate of transfection inhibition.

Lane 1 (Fig. 61),

containing 8 ug of unincubated fl DNA, shows that 80-90

of the starting

DNA is in intact closed circular form. Incubation with 50 mM G6P (lane
4) decreases the amount of intact DNA by about one-half when compared
with the starting material, so that the amount of intact circles is
roughly equal to the amount of linear DNA present.

If DNA breakage

events follow a Poisson distribution, then about one-third of the

Figure 61. Alkaline gel electrophoresis of fl DNA that
had been incubated with 10, 50, 100, or 150 mM G6P (lanes
3-6) or 50 or 150 mM glucose (lanes 7 and 8 ) . Lane 1: unincubated DNA. Lane 2: DNA incubated without sugar.

Figure 62. Alkaline gel electrophoresis of fl DNA
14
that had been incubated with [ C]G6P for 6 days
(lane 2) or 14 days (lane3). Lane 1: unincubated
fl DNA. Lane 4: the same DNA treated, immediately
prior to electrophoresis, with [ C]G6P that had
been incubated alone for 14 days. (A): Ethidium
bromide staining. (B): Fluorography.
circular DNA. 1: linear DNA.

cc: closed
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original molecules should remain unnicked when the number of linear and
circular molecules are equal.

Under the same incubation conditions

however, transfection efficiency was decreased by more than two orders
of magnitude (Fig. 60). While we cannot exclude contaminating nuclease
activity, it alone cannot account for the observed decrease in
transfection efficiency.
inhibit template

The initial G6P adduct may be sufficient to

activity

and, with time, further reaction

or

rearrangement occurs that destabilizes the phosphodiester backbone and
causes DNA degradation.
The time dependent decrease in transfection efficiency of fl DNA
after incubation with 25 mM G6P or glucose is shown in Figure 63.
Inhibition was also first order with respect to incubation time.

Figure

63 in addition, shows the inhibition kinetics for these sugars in the
presence of 5 mM N-a-t-Boc-lysine.

The e-amino group of lysine should

be far more reactive toward reducing sugars than the primary amino
groups of nucleotides which, because of tautomerlzation, possess partial
secondary character.
should

thus

The presence of lysine in the incubation mixture

accelerate

the Maillard

process.

Studies

of the

nonenzymatic browning of proteins have shown that products of the later
stages of the Maillard process are highly reactive, can crosslink
proteins, and may even be mutagenic (53, 144).
As shown in Figure 63, the rate of transfection inhibition is
initially less in the presence of Boc-lysine.

With longer incubation

times, transfection efficiency decreases, reaching a rate that is more
rapid than the rate for either glucose or G6P alone.

This pattern leads

to the hypothesis that the amino group of the lysine initially consumes
enough of the sugar to inhibit its reaction with DNA, and that with
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time, reactive Maillard intermediates are generated by the reaction of
G6P with Boc-lysine.

An alternative explanation is that lysine promotes

the rate of chain breakage at apurinic sites, as has been previously
been shown for a number of amines (145). This 1s unlikely under our
experimental conditions because gel electrophoresis at various times of
DNA incubated with G6P or with G6P/Boc-lysine showed no discernible
difference in the progressive decrease of closed circular DNA (Fig. 64).
Products formed from the reaction of nucleic acids with simple
alkylating agents often vary depending on whether the polynucleotide is
in a double- or a single-stranded form.

This occurs in cases in which

modification affects amino positions that are hydrogen bonded in the
double-stranded molecule (146).

These sites are less reactive, although

some reaction at these sites will occur as a result of thermal
denaturation (147). fl exists as a ds DNA during its replicative phase.
Purified Rfl (fl, replicative form) was incubated with 150 mM G6P under
the conditions described previously for single-stranded f1.
Trsnsfection analysis of Rfl modified by incubation with G6P for 1 and
33 weeks showed inhibitory effects of 0.5 and 4 orders of magnitude,
respectively.

Gel electrophoresis of samples incubated for 3 weeks

showed substantial (90%) chain breakage (data not shown).

We next examined the mutagenicity of G6P induced lesions in the
double-stranded DNA plasmid pBR322. This plasmid contains two
selectable genes, an£ and tet, which confer resistance to the
antibiotics ampicillin and tetracycline respectively, on an E. coli host
(148).

Plasmid DNA was Incubated with G6P in vitro and aliquots

transformed into the E.coli strain, K38. As shown in Figure 65, a total
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of 17 Amp'^Tets mutants (designated pBRGMl-pBRGMl 7) were isolated.
Appreciable numbers of mutants were detected only after the transforming
capacity of the plasmid DNA had been reduced by over 4 orders of
magnitude.
The isolated mutants were tested for their level of antibiotic
sensitivity.

Utilizing both microbial susceptibility discs (149) and

growth on antibiotic gradient plates (150), it was found that each
mutant displayed a level of ampicillin resistance equivalent to that of
cells bearing wild-type pBR322 and a level of tetracycline sensitivity
equivalent to that of the uninfected K38 host.

Mutants also were tested

for Tets by positive selection on medium containing fusaric acid (151).
This lipophilic chelating agent inhibits the growth of Tef^ cells via
its toxic interaction with a tet*^ gene product.

Unexpectedly, one of

the Amp'^Tets strains (pBRGMIS) was found to be sensitive to fusaric
acid.

This plasmid evidently bears an unusual mutation which

inactivates Tet*^ function but does not affect the toxic effect of
fusaric acid.
In order to investigate structural changes in the mutant plasmids,
low molecular weight DNA was prepared from subclones of the original
isolates which had been maintained by serial transfer on ampicinin
supplemented media (50 ug/ml).

In the case of 13 of the 17 mutants, DNA

yields were found to be far below expectation, even for single-copy DNA
plasmids.

Surprisingly, antibiotic sensitivity analysis of colonies

derived from single cells of these subclones revealed that in these
isolates, the Amp*^ phenotype persisted but that resistance had decreased
from a wild-type pBR322 level of greater than 200 ug/ml to about 50
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[G6P]

OmM
ISOmM
200mM

OmM
300mM
400mM

Incubation
time

Inactivation
log

25d

.08
3.2
4.2

250
172
46*

0
2
0

< 0.4

.05
5.1
5.9

300
344
304

0
5
10

< 0.3

II
II

14d
II
II

Colonies
tested

Amp^Tet^

Percent mutation
of survivors

1.1
< 2.2

1.3
3.3

*only 45 colonies recovered.

2
4
6
log (inactivation)

Figure 65. Summary of transformed single colonies assayed on selective
media. The graph shows mutation frequency versus the log of plasmid inactivation. Inactivation, or the loss of transformation capacity, was calculated from the number of Amp colonies appearing after transformation with
control DNA minus the number appearing with G6P-treated DNA.
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ug/ml (Fig. 66). Thus, ampicillin resistance in these subclones must
have been the result of intense selection for chromosomal resistance in
the E. coli. host.

This hypothesis was confirmed by Southern

hybridization analysis of total DNA from these Amp'^ subclones.
Utilizing both a 32p_pBR322 probe and a single-copy gene probe as a
control, no sequence homology between pBR322 and whole cellular DNA was
detected (Fig. 67).
The fraction of cells remaining Amp^ in overnight liquid cultures
which had been inoculated from the original transformed colonies was
then determined.

A varying loss of the Amp'^ phenotype was observed,

presumably as the result of plasmid segregation.

Therefore, the

mutation in 13 of the plasmids leads not only to a loss of tetracycline
resistance but also to the inactivation of function(s) required for
stable replication.

Furthermore, maintenance of these slowly

segregating Amp'^Tet^ plasmid bearing strains on ampicillin supplemented
media resulted, in each case, in the emergence of E. coli colonies which
had developed chromosomal resistance to high levels of ampicillin.
DNA from the plasmid bearing strains was then analyzed by Southern
hydridization using, as substrate, whole E.coli DNA prepared from a
liquid culture inoculated from the original transformed colony.

A

chimeric plasmid consisting of pBR322 and an E. coli DNA fragment
containing the thioredoxin gene (152) was labeled by nick-translation
and used as a probe.

Since the thioredoxin gene is present in only a

single copy in the E.coli chromosome, comparison of the hybridization
intensity of this sequence with plasmid sequences would indicate loss of
plasmid copy number due to rapid segregation.

Figure 68 shows the

hybridization pattern obtained for whole E.coli DNA derived from 16 of

Figure 66. Ampicillin resistance level measured
with ampicillin gradient plates. K38'Amp^l and
K38»Amp 2 denote two subclones isolated from the
original mutant-plasmid bearing colonies. pBRGMlpBRGM17 denote the resistance phenotype of the
original mutant-plasmid bearing colonies.

AMPICILLIN RESISTANCE LEVEL

pBR322
K38
K38Amp'l
K38Amp'2
pBRGMIpBRGMI?
[ampiciMin]
yu.g/ml
150

Figure 67. Southern hybridization analysis of
whole E. coli DNA derived from the amp subclones
(pBRGMl* - pBR6M9*) and pBR322 bearing K38. DNA
32
was probed with a chimeric
P-pBR322-thioredoxin
gene plasmid, both with (+) and without (-) prior
digestion with the restiction enzymes Hind III or
Sal I. trx: the position of the host, single-copy
thioredoxin gene.

1: linear plasmid sequences.

sc: supercoiled plasmid sequences.

^

4^

*

"l

^

\^

#

i Hr

•

i

«
trx
•pBR322,[L]

pBR322,[sc]
+ + - + t

- + + - +

+ - + +

Restriction enzyme
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the 17 mutants.

The hybridization intensity of pBRGMl3, for example, is

yery low relative to wild-type pBR322 and roughly equivalent to the
intensity of the thioredoxin gene (Fig. 68A and B ) . Thus the copy
number of this plasmid has substantially decreased relative to wild-type
pBR322 and a significant amount of plasmid segregation had occurred
during growth in liquid culture.
Alternating lanes in Fig. 68 show DNA digested with the restriction
enzyme Hind III, which cleaves wild-type pBR322 at a single site and
converts the rapidly migrating supercoiled form into a linear molecule
which migrates as a function of its molecular weight (153).

Cleavage

also serves to reduce multimeric but otherwise identical plasmids to a
single species.

Plasmid multimers occur spontaneously during the

replication of unmutagenized pBR322. Four mutants show the presence of
a large insertion (pBRGMl, pBRGM4, pBRGM12, and pBRGMIS), and five show
large deletions (pBRGM2, pBRGM7, pBRGMS, pBRGMIS, and pBRGMU).

Eight

of the 17 mutant plasmids appear to be the same size as wild-type pBR322
and presumably bear mutations which involve a small number of
nucleotides (<50 bp). Table 13 summarizes the characteristics of the
different mutants and lists the molecular weight of the hybridizing
bands present in the Hind III treated samples.

Eight of the undigested

lanes appear to contain small amounts of additional supercoiled plasmids
which are larger in size than the major hybridizing species.

In the

case of four of these mutants (pBRGMS, pBRGM6, pBRGMIO, and pBRGM12),
Hind III cleavage gives rise to DNA fragments whose sizes suggest that
they are linear monomers and dimers (Table 13). Thus, the highest
molecular weight Hind III fragment is most likely the product of
incomplete digestion of the parent dimer.

In the case of four other

Figure 68. (A) Southern hybridization of whole E. coli
DNA from cells containing the mutant plasmids (pBRGMlpBRGM16), wild type plasmid (pBR322), and no plasmid
(K38). The lane marked STDs includes base-pair markers
obtained from an Eco RII restriction digestion of
pBRGMIS plus a sample of pBRGMIS cleaved with Hind III.
[sc]: denotes supercoiled pBR322. [1]: denotes linear
form pBR322. thrd.: indicates the chromosomal DNA
fragment containing the thioredoxin gene.
(B): Autoradiogram of pBRGMIS lane exposed for longer
than in (A) in order to demonstrate the comparable
hybridization intensities of pBRGMIS and the thioredoxin
gene.
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Plasmid
PBR322
pBRGMl
pBRGM2
pBRGMS
pBRGM4
pBRGMS
pBRGM6
pBRGM7
pBRGMS
pBRGM9
pBRGMl0
pBRGMl1
pBRGMl2
pBRGMIS
pBRGMl4
pBRGMIS
pBRGMl6
pBRGMl7

Segregation
Phenotype

Fusaric Acid
Sensitivity

+
+
+
+
+
+
+
+
+
+
+
+
+
-

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

DNA (bp)
4363
5200
3500f",
4360
4700ni,
4360ni,
4360ni,
3600
35001",
4360
4360,
4360
5400"',
3000
SSOO"',
5131
4360
4360

Table 13. Summary of mutant characteristics.

9800
9800
9800^
9800^
9800
9800^
7400, 11,000<^
9800

DNA size is derived

from Hind III digested samples and is estimated from a plot of
log[bp] versus Rf and the 6 DNA standards described in Figure 2.
The DNA size of pBRGMl7 was determined in separate experiments
not displayed in Figure 2.

(m):denotes the major species,

(d):denotes a probable dimer form.
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mutants, (pBRGM2, pBRGM4, pBRGMS, and pBRGMU), Hind III treatment
produces fragments whose sizes do not correspond to products of a single
plasmid species plus an associated multimer.
from these clones contain several

Therefore, cells derived

plasmid species; a predominant

low-molecular weight plasmid and small amounts of a pBR322-dimer size
molecule.
A mutant displaying stable replication

(pBRGMIS) was further

analyzed in order to ascertain the origin of its large insertion.
Southern hybridization with a 32p_pBRGM15 probe of E.col 1 DNA from a
strain lacking plasmid demonstrated the presence of host sequences
complementary to pBRGMIS (Fig. 69). Sequential restriction mapping of
pBRGMIS with the enzymes EcoR II and Sal 1 demonstrated that the
insertion is located within the tet^ gene, is 770 bp in length, and
contains an Eco RII site about one-sixth of the distance from one end
(Figure 70). These data are consistent with the interpretation that
pBRGMIS has acquired the insertion element ISl;

a mobile element

present in the E.coli genome which is 768 bp long and contains a single
Eco RII site 655 bp downstream from its origin (154).
To inquire into the possible role of DNA repair mechanisms in the
expression of G6P induced DNA lesions, pBR322 DNA modified by incubation
with G6P was transformed into a uvrC" strain (K704).

This strain lacks

one subunit of the uvrABC excision nuclease, an enzyme which has been
shown to remove a number of bulky DNA adducts (155, 156)

Transformation

of modified DNA into this strain was found to result in no detectable
mutagenesis (0 of 648 colonies screened).

Transformation of DNA from

the same incubation mixture into strain K38 produced mutations at the
expected frequency.

This result would appear to implicate the uvrABC

Figure 69. Southern hybridization of whole E. coli
DNA from host strain K38 and strain K38 bearing the
plasmid pBR322. (left): DNA probed with the chimeric
32
thioredoxin gene containing plasmid,
P-pBR322*trx.
(right): DNA probed with the mutant plasmid ^^P-pBRGM15.
trx: position of the chromosomal thioredoxin gene.
1: linear form pBR322. sc: supercoiled pBR322. The
right arrows denote sequences present in K38 which are
complementary to pBRGMIS.

Hindlll - + - + - + - +
.
•
•

trx->
p.BR322(l)^

pBR322(sc)^

•

•

•

•

t

<-

^ ^

%

«

32P-pBR322-trx 32P-pBRGMI5

Eco RII

Figure 70.

Position of the insertion element

ISl in the plasmid pBRGMIS as determined by
restriction enzyme mapping.
kb. units.

The numbers denote

The outside lines show the position

of Eco RII sites.
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nuclease in the induction of mutagenic lesions.

The gross chromosomal

alterations observed in a number of the pBRGM mutants however, do not
appear to be characteristic of the simple excision repair activity
described for this enzyme and may be indicative of more extensive damage
which is only partially excised.
The in vitro inactivation of double-stranded pBR322 allows one to
predict the frequency of G6P damage which may be occuring in a larger
genome.

Although one naturally must be circumspect in this type of

estimation, it does signify possible biological relevance.

Figure 71

shows the loss of the capacity of pBR322 to transform E.coli to Amp'^
with time.

This data is derived from the results of Figure 65. Loss of

transformation is linear with time and proceeds at a rate which is 4.5
orders of magnitude slower than the rate of single-stranded phage DNA
(Figure 60).

Assuming that DNA damage is proportional

to G6P

concentration (Figure 60) and that the Intracellular G6P concentration
is 0.25 mM (159), then a 4.2 log inactivation (25 days for 200 mM G6P,
Fig. 71) for the ampicillin gene would Indicate that the human genome on
the average might suffer 2.7 G6P "hits" per day.

Additonal damage would

be anticipated from the reaction of other reducing sugars, e.g. glucose,
glyceraldehyde-3-P04, with DNA.
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Figure 71. The loss of the ability of pBR322 to transform
E.coli to Amp^ with time at 0 mM 66P (o), 150 mM G6P (§),
and 200 mM G6P (•).
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B.

Conclusion.

The incubation of DNA or single nucleotides leads to absorbance and
fluorescence changes which suggest that DNA can be glycosylated and
undergo nonenzymatic browning.

Spectral changes were not observed with

TMP, which lacks a primary amino group, nor with ds DNA, in which
hydrogen bonding may hinder the amino groups from reacting.

Incubation

of single-stranded viral DNA with these sugars causes a time and
concentration dependent decrease in transfection efficiency.

G6P also

was observed to induce strand scission at a rate slower than the rate of
transfection inhibition.
These results suggest that G6P, and glucose at a much slower rate,
forms adducts with the primary amino groups of bases that inhibit template function.

With time, these adducts undergo chemical rearrangement

that in a manner analogous to DNA alkylating agents, can labilize the
glycosidic bond between the purine and the deoxyribose.

This leads to

depurination and, after still more time, B-el1m1nation and strand
scission.
DNA which has been nonenzymatically modified by G6P in vitro
also leads to mutations in a prokaryotic host.
mutants provided two surprizing observations.

Analysis of these
The first is that the

majority of the Isolated mutants (76%) are unstable and undergo
segregation.

This result was unexpected but probably is not specific

for G6P induced damage.

It is possible that DNA damaging agents in

general, lead to a high percentage of unstable mutants, but that progeny
from these mutants are rapidly lost and escape detection.
The second unusual finding is the striking degree of DNA alteration
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which had occurred in several of the isolated mutants.

The one stable

plasmid which was analyzed appears to contain the common E. coli
insertion element ISl, but other mutant plasmids most likely have
undergone more dramatic structural changes.

The mechanism by which

these DNA alterations arise is unknown, but is presumably the result of
single, and perhaps multiple deletions, insertions, or duplications.
Preliminary experiments implicate the uvrABC pathway in the expression
G6P induced mutations, but the DNA rearrangements observed appear not to
be characteristic

of simple nucleotide adducts and may be the

consequence of extensive damage such as interstrand cross-linkage.
Products formed from the in vivo reaction of reducing sugars with
nucleic acids have not yet been isolated.

The occurence of these

products however, seems likely in view of the reactivity of DNA toward
reducing sugars, the long-life of nucleic acids in the resting cell, and
much evidence indicating that proteins undergo nonenzymatic glycosylation in vivo.

The observation that an intracellular metabolite can

modify DNA suggests a mechanism for the accumulation of genetic lesions
that may lead to cellular senescence.

Free amines within the cell might

further contribute to DNA damage by nonenzymatic browning, as the experiments with the simultaneous incubation of Boc-lysine suggest.

The

occurence of Maillard products on nuclear proteins might account for the
increased crosslinking of proteins to DNA that has been observed in the
chromatin of aged organisms (157).

Alternatively, basic proteins, which

are bound to at least 50% of the mammalian genome (158), may play a protective, shielding role.

In any event, the induction of nucleic acid

damage by endogenous sugars implies that nonenzymatic reactions of this
type may contribute to the decreased genetic viability and increased
tumorigenesis observed in the aged organism.
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